<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rivaroxaban: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rivaroxaban: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rivaroxaban: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9498" href="/d/html/9498.html" rel="external">see "Rivaroxaban: Drug information"</a> and <a class="drug drug_patient" data-topicid="12198" href="/d/html/12198.html" rel="external">see "Rivaroxaban: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13135512"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Premature discontinuation increases the risk of thrombotic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Premature discontinuation of any oral anticoagulant, including rivaroxaban, increases the risk of thrombotic events. If anticoagulation with rivaroxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Spinal/Epidural hematomas:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Epidural or spinal hematomas have occurred in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; or a history of spinal deformity or spinal surgery. The optimal timing between the administration of rivaroxaban and neuraxial procedures is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefits and risks before neuraxial intervention in patients who are anticoagulated or are to be anticoagulated for thromboprophylaxis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13107816"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xarelto;</li>
<li>Xarelto Starter Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868973"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Rivaroxaban;</li>
<li>PMS-Rivaroxaban;</li>
<li>PRO-Rivaroxaban;</li>
<li>REDDY-Rivaroxaban;</li>
<li>RIVA-Rivaroxaban;</li>
<li>SANDOZ Rivaroxaban;</li>
<li>TARO-Rivaroxaban;</li>
<li>TEVA Rivaroxaban;</li>
<li>Xarelto</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28120259"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anticoagulant</span>;</li>
<li>
<span class="list-set-name">Anticoagulant, Factor Xa Inhibitor</span></li></ul></div>
<div class="block don drugH1Div" id="F56523955"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism (VTE):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment </i>(<i>after stabilization with ≥5 days of initial parenteral treatment): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Begin treatment after at least 10 days of oral feeding. Recommended duration of treatment is 3 months (up to 12 months when clinically appropriate) unless treating a catheter-related VTE where the recommended duration of treatment is 1 month (up to 3 months when clinically appropriate):</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥37 weeks: Oral suspension:</p>
<p style="text-indent:-2em;margin-left:8em;">2.6 to 2.9 kg: Oral: 0.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">3 to 3.9 kg: Oral: 0.9 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 4.9 kg: Oral: 1.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">5 to 6.9 kg: Oral: 1.6 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis against recurrence (after stabilization with ≥5 days of initial parenteral treatment)</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Begin treatment after at least 10 days of oral feeding.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥37 weeks: Oral suspension:</p>
<p style="text-indent:-2em;margin-left:8em;">2.6 to 2.9 kg: Oral: 0.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">3 to 3.9 kg: Oral: 0.9 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 4.9 kg: Oral: 1.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">5 to 6.9 kg: Oral: 1.6 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function</b>: Neonates ≥2.6 kg: Due to limited clinical data, avoid use when serum creatinine is above the 97.5th percentile (manufacturer's labeling). See "Dosing: Altered Kidney Function: Pediatric" for reference values of serum creatinine in infants ≥2.6 kg.</p></div>
<div class="block dop drugH1Div" id="F54282219"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd4d584c-5001-4c0c-9000-04e9c94600b4">Thromboprophylaxis after Fontan procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboprophylaxis after Fontan procedure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral suspension: </i></p>
<p style="text-indent:-2em;margin-left:8em;">7 to 7.9 kg: Oral: 1.1 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">8 to 9.9 kg: Oral: 1.6 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">10 to 11.9 kg: Oral: 1.7 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">12 to 19.9 kg: Oral: 2 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">20 to 29.9 kg: Oral: 2.5 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to 49.9 kg: Oral: 7.5 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: Oral: 10 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral tablet:</i>
<b>Note:</b> Rivaroxaban 2.5 mg tablets are not recommended for use in pediatric patients; safety, efficacy, and pharmacokinetic/pharmacodynamic data are lacking for this dosage form.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: Oral: 10 mg/dose every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e773a39f-176a-42f9-b942-8ed646b3aec0">Venous thromboembolism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism (VTE): </b>
<b>Note:</b> Dosing based on the EINSTEIN-Jr phase 3 study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699660','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699660','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i> (<i>after stabilization with ≥5 days of initial parenteral treatment):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Begin treatment after at least 10 days of oral feeding. Recommended duration of treatment is 3 months (up to 12 months when clinically appropriate) unless &lt;2 years of age with catheter-related VTE where recommended duration of treatment is 1 month (up to 3 months when clinically appropriate):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral suspension: </i></p>
<p style="text-indent:-2em;margin-left:10em;">2.6 to 2.9 kg: Oral: 0.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 3.9 kg: Oral: 0.9 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to 4.9 kg: Oral: 1.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">5 to 6.9 kg: Oral: 1.6 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">7 to 7.9 kg: Oral: 1.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">8 to 8.9 kg: Oral: 2.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">9 to 9.9 kg: Oral: 2.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 11.9 kg: Oral: 3 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">12 to 29.9 kg: Oral: 5 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">30 to 49.9 kg: Oral: 15 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 20 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral tablet:</i>
<b>Note: </b>Rivaroxaban 2.5 mg tablets are not recommended for use in pediatric patients; safety, efficacy, and pharmacokinetic/pharmacodynamic data are lacking for this dosage form.</p>
<p style="text-indent:-2em;margin-left:10em;">30 to 49.9 kg: Oral: 15 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 20 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis against recurrence (after stabilization with ≥5 days of initial parenteral treatment)</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Begin treatment after at least 10 days of oral feeding:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral suspension:</i></p>
<p style="text-indent:-2em;margin-left:10em;">2.6 to 2.9 kg: Oral: 0.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to 3.9 kg: Oral: 0.9 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to 4.9 kg: Oral: 1.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">5 to 6.9 kg: Oral: 1.6 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">7 to 7.9 kg: Oral: 1.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">8 to 8.9 kg: Oral: 2.4 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">9 to 9.9 kg: Oral: 2.8 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 11.9 kg: Oral: 3 mg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">12 to 29.9 kg: Oral: 5 mg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">30 to 49.9 kg: Oral: 15 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 20 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral tablet:</i>
<b>Note: </b>Rivaroxaban 2.5 mg tablets are not recommended for use in pediatric patients; safety, efficacy, and pharmacokinetic/pharmacodynamic data are lacking for this dosage form.</p>
<p style="text-indent:-2em;margin-left:10em;">30 to 49.9 kg: Oral: 15 mg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 20 mg/dose every 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between anticoagulants:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transitioning from another anticoagulant to rivaroxaban:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from unfractionated heparin (UFH) by continuous infusion to rivaroxaban: Discontinue infusion and start rivaroxaban at the same time.</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from warfarin to rivaroxaban: Discontinue warfarin and initiate rivaroxaban as soon as INR falls to &lt;2.5.</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from anticoagulant other than warfarin to rivaroxaban (eg, low molecular weight heparin [LMWH], non-warfarin oral anticoagulant): Start rivaroxaban within 2 hours prior to the next scheduled dose of the anticoagulant agent. Discontinue the other anticoagulant.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transitioning from rivaroxaban to another anticoagulant:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from rivaroxaban to anticoagulant with rapid onset (oral or parenteral): Start anticoagulant when the next dose of rivaroxaban was scheduled to be given.</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from rivaroxaban to warfarin: Initiate warfarin and continue rivaroxaban for ≥2 days after first dose warfarin. After 2 days of coadministration, check an INR prior to the next scheduled dose of rivaroxaban. Continue coadministration of warfarin and rivaroxaban until INR ≥2. <b>Note: </b>In adults, rivaroxaban has been shown to elevate the INR and can complicate interpretation when overlapped with warfarin; perform INR monitoring when rivaroxaban is at its trough concentration (Moore 2015). INR monitoring is reliable 24 hours after last dose of rivaroxaban.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning between anticoagulants in the perioperative setting: </i></b>Discontinue rivaroxaban ≥24 hours before procedure. Decision to delay surgery or procedure until 24 hours after last dose of rivaroxaban should be based upon increased risk of bleeding and urgency of surgery/procedure. Rivaroxaban should be restarted as soon as adequate hemostasis is established following surgery/procedure. Consider a parenteral anticoagulant if oral administration is not possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54282220"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2.6 kg: <b>Note: </b>Due to limited clinical data, avoid use when serum creatinine is above the 97.5th percentile (manufacturer's labeling).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Reference Values of Serum Creatinine (Boer 2010)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Age<sup>a</sup></p></th>
<th align="left">
<p style="text-indent:0em;">97.5th Percentile of Creatinine (mg/dL)</p></th>
<th align="left">
<p style="text-indent:0em;">97.5th Percentile of Creatinine (µmol/L)</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Values are derived from term infants (&gt;37 weeks) without kidney impairment.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">0.52 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">46 µmol/L</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">0.46 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">41 µmol/L</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">0.42 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">37 µmol/L</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">2 months</p></td>
<td align="left">
<p style="text-indent:0em;">0.37 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">33 µmol/L</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3 to 9 months</p></td>
<td align="left">
<p style="text-indent:0em;">0.34 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">30 µmol/L</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 to 12 months</p></td>
<td align="left">
<p style="text-indent:0em;">0.36 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;">32 µmol/L</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (eGFR should be calculated using the Modified Schwartz equation when isotope dilution mass spectrometry (IDMS) calibrated method is used for SCr measurement):</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 50 to 80 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (Willmann 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;50 mL/minute/1.73 m<sup>2</sup>: Avoid use (very limited data available in this population) (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent: </b>Not dialyzable (&lt;5%) based on adult studies (Dias 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Use not recommended based on adult recommendations; data for use in pediatric patients is lacking (Dager 2018).</p></div>
<div class="block dohp drugH1Div" id="F54282221"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling (no clinical data). Avoid use in patients with hepatic disease associated with either coagulopathy leading to a clinically relevant bleeding risk or alanine aminotransferase &gt;5 x ULN or total bilirubin &gt;2 x ULN with direct bilirubin &gt;20% of the total; these patients were excluded from the pediatric clinical trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699660'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F6724168"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9498" href="/d/html/9498.html" rel="external">see "Rivaroxaban: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">The adult dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editor: Edith A Nutescu, PharmD, MS, FCCP.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3b0fbf5-2b81-46af-9547-44424196af7e">Atrial fibrillation, nonvalvular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg once daily with the evening meal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Postpercutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation (off label):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 15 mg once daily with food; administer with an appropriate antithrombotic regimen including clopidogrel (preferred P2Y12 inhibitor in this situation) with or without aspirin, depending on risk for thrombosis and bleeding, and time since percutaneous coronary intervention (PCI) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-27959713','lexi-content-ref-32176890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-27959713','lexi-content-ref-32176890'])">Ref</a></span>). It is recommended to discontinue aspirin 1 to 4 weeks after PCI and continue rivaroxaban and clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4194cfb2-445d-4503-a1c3-1792c428259d">Coronary artery disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute coronary syndrome (after stabilization with initial management) (off label): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>As add-on to clopidogrel (<b>not</b> prasugrel or ticagrelor) and aspirin therapy in patients who are not at high risk of bleeding and do not require chronic therapeutic anticoagulation for another indication; patient preference should also be taken into consideration given the higher risk of bleeding when adding rivaroxaban to dual antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lip.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lip.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2.5 mg twice daily; administer in combination with low dose aspirin plus clopidogrel; continue rivaroxaban for ~1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lip.2020','lexi-content-ref-22077192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lip.2020','lexi-content-ref-22077192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Coronary artery disease, stable: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May consider for use in patients who are at high risk of cardiovascular events and low risk of bleeding if therapeutic anticoagulation is not required for another indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28844192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28844192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2.5 mg twice daily; administer in combination with daily low dose aspirin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For treatment of acute heparin-induced thrombocytopenia (HIT), either as initial therapy in selected hemodynamically stable patients or after initial therapy with a parenteral non-heparin anticoagulant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27632140','lexi-content-ref-27075620','lexi-content-ref-28646118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27632140','lexi-content-ref-27075620','lexi-content-ref-28646118'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>HIT with or without thrombosis</i>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 15 mg twice daily with food for 21 days or until platelet count recovery, whichever is longer, followed by 20 mg once daily with food.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> If initially treated with a parenteral non-heparin anticoagulant, can transition to 20 mg once daily after platelet count recovery. However, if the parenteral non-heparin anticoagulant is administered for &lt;21 days, transition to 15 mg twice daily; then, after a total of 21 days with non-heparin anticoagulation, reduce to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coutre.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coutre.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration:</i> Not well established:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIT without thrombosis:</i> Typically, 4 weeks to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270'])">Ref</a></span>). Alternatively, may discontinue anticoagulation after platelet count recovery, potentially resulting in a shorter duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIT with thrombosis:</i> Typically, 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-30482768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba3cac22-92f3-4d91-8b64-a71094493945">Left ventricular thrombus, treatment or prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Left ventricular thrombus, treatment or prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Post myocardial infarction</i>:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for myocardial infarction (MI) may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 20 mg once daily for ~3 months in patients with acute MI or ≥3 to 6 months in patients with distant MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33766266','lexi-content-ref-36106537','lexi-content-ref-32583975','lexi-content-ref-30656027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33766266','lexi-content-ref-36106537','lexi-content-ref-32583975','lexi-content-ref-30656027'])">Ref</a></span>). Duration may vary based on follow-up imaging (eg, assessment of thrombus resolution and left ventricular [LV] function) and shared decision making; indefinite therapy may be considered if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Nonischemic dilated cardiomyopathy:</i> Oral: </b>20 mg once daily for ≥3 to 6 months; duration may vary based on follow-up imaging (eg, assessment of thrombus resolution and LV function) and shared decision making; indefinite therapy may be considered even after thrombus resolution if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33766266','lexi-content-ref-36106537','lexi-content-ref-32583975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33766266','lexi-content-ref-36106537','lexi-content-ref-32583975'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prophylaxis for high-risk patients post myocardial infarction:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used for high-risk patients (eg, ejection fraction &lt;40% and/or anteroapical wall motion abnormality) to prevent LV thrombus. When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for MI may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-23247304','lexi-content-ref-22315274','lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-23247304','lexi-content-ref-22315274','lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 mg once daily for 1 to 3 months; duration may vary based on follow-up imaging (eg, assessment of LV function) and shared decision making (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="868c6e16-2720-44ae-9b89-408e1b9f689a">Peripheral artery disease, stable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral artery disease, stable: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider for use in patients who are at low risk of bleeding and at high risk of major thrombotic vascular events, including after recent lower extremity revascularization. When starting after lower extremity revascularization, initiate when hemostasis is achieved. Do not use if dual antiplatelet therapy is planned or therapeutic anticoagulation is required for another indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222135','lexi-content-ref-28844192','lexi-content-ref-33023325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222135','lexi-content-ref-28844192','lexi-content-ref-33023325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 mg twice daily; administer in combination with daily low dose aspirin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecba0286-174b-43f1-b4e1-06dd8e2abeb8">Superficial vein thrombosis, acute symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Superficial vein thrombosis, acute symptomatic (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider as an alternative to fondaparinux for use in patients at increased risk for thromboembolism or with recurrent superficial vein thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily for 45 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219692'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e773a39f-176a-42f9-b942-8ed646b3aec0">Venous thromboembolism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Deep vein thrombosis and/or pulmonary embolism treatment:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used in patients with active cancer (eg, metastatic disease, receiving chemotherapy); however, avoid use in patients with upper GI tract cancers due to increased bleeding risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-31381464','lexi-content-ref-33351124','lexi-content-ref-29746227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-31381464','lexi-content-ref-33351124','lexi-content-ref-29746227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 15 mg twice daily with food for 21 days followed by 20 mg once daily with food.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i> Duration of therapeutic anticoagulation (first episode, general recommendations):</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences:</p>
<p style="text-indent:-2em;margin-left:8em;">Provoked venous thromboembolism: 3 months (provided the provoking risk factor is no longer present) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Unprovoked venous thromboembolism or provoked venous thromboembolism with a persistent risk factor: ≥3 months depending on risk of venous thromboembolism (VTE) recurrence and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-22332937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-22332937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Indefinite anticoagulation (reduced intensity dosing for prophylaxis against venous thromboembolism recurrence):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For patients at elevated risk of recurrent VTE following ≥6 months of therapeutic anticoagulation. This reduced-intensity regimen is <b>not</b> recommended if indefinite full anticoagulation is indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28316277','lexi-content-ref-Lip.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28316277','lexi-content-ref-Lip.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28316279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28316279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Venous thromboembolism prophylaxis:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acutely ill medical patients:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 10 mg once daily for a total duration of 31 to 39 days (including hospitalization and postdischarge) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23388003','lexi-content-ref-30145946','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23388003','lexi-content-ref-30145946','lexi-content-ref-manu.1'])">Ref</a></span>). Some experts prefer LMWH as prophylaxis during acute hospitalization and suggest not routinely extending prophylaxis beyond discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2019'])">Ref</a></span>). However, in high-risk coronavirus disease 2019 (COVID-19) patients who are discharged from the hospital, some experts would consider extended prophylaxis for a total of 31 to 39 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cuker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cuker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Nonmajor orthopedic surgery of lower limb (alternative therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Early ambulation alone is preferred when feasible, but pharmacologic prophylaxis may be considered for patients with higher than usual risk (eg, history of venous thromboembolism, limited mobility, or undergoing high risk surgery such as Achilles tendon repair, femoral fracture, tibial plateau fracture, or ligament repair of the knee) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2020','lexi-content-ref-32223113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2020','lexi-content-ref-32223113'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>10 mg once daily initiated ≥6 to 10 hours after surgery; continue for the duration of immobilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2020','lexi-content-ref-32223113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2020','lexi-content-ref-32223113'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Total hip arthroplasty or total knee arthroplasty</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 10 mg once daily initiated ≥6 to 10 hours after surgery or when hemostasis established.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Duration:</i> Optimal duration of prophylaxis is unknown but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-11454370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-11454370'])">Ref</a></span>); some experts suggest a duration in the lower end of the range (10 to 14 days) for total knee arthroplasty (TKA) or higher end of range (30 days) for total hip arthroplasty (THA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> In carefully selected patients at low risk of VTE who are undergoing elective, unilateral THA or TKA, an alternative approach to prophylaxis is to give rivaroxaban 10 mg once daily for 5 days then switch to aspirin for an additional 30 days for THA or 9 days for TKA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29466159','lexi-content-ref-Pai.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29466159','lexi-content-ref-Pai.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between anticoagulants:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to rivaroxaban:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from low-molecular-weight heparin or fondaparinux (therapeutic dose) to rivaroxaban: Discontinue the parenteral anticoagulant and initiate rivaroxaban within 2 hours prior to when the next scheduled dose of the parenteral anticoagulant was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from unfractionated heparin continuous infusion to rivaroxaban: Start rivaroxaban when the unfractionated heparin infusion is stopped (consult local protocol if aPTT is above the target range) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from warfarin to rivaroxaban: Discontinue warfarin and initiate rivaroxaban when INR is &lt;3 (US labeling) or ≤2.5 (Canadian labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from rivaroxaban to another anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from rivaroxaban to a parenteral anticoagulant: Start the parenteral anticoagulant when the next dose of rivaroxaban was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from rivaroxaban to warfarin:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Rivaroxaban can elevate the INR, complicating interpretation if overlapped with warfarin. To minimize interference, check INR near the end of rivaroxaban dosing interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Some experts suggest overlapping rivaroxaban with warfarin until INR is within the therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482765'])">Ref</a></span>). An alternative is to stop rivaroxaban, then start warfarin the same day and bridge with a parenteral anticoagulant until INR is within the therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Transitioning between direct oral anticoagulants:</b></i> Start new direct oral anticoagulant (DOAC) when the next dose of previous DOAC was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990333"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> Clinical trials evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (weight range of patients enrolled in clinical trials: 33 to 209 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>). Monitor for worsening kidney function. Discontinue in patients who develop acute kidney failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism):</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 50 mL/minute: 15 mg once daily with the evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-30686041'])">Ref</a></span>). Patients with CrCl &lt;30 mL/minute were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21830957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21830957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Avoid use; apixaban or warfarin is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-30686041'])">Ref</a></span>). Patients with CrCl &lt;15 mL/minute were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21830957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21830957'])">Ref</a></span>); currently no other clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056'])">Ref</a></span>). The US manufacturer's labeling recommends 15 mg once daily in this population based on a single-dose (10 mg) pharmacokinetic study that did not evaluate clinical outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21039764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21039764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>). Limited and conflicting data are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25595139','lexi-content-ref-31054829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25595139','lexi-content-ref-31054829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Postpercutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation (off label):</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: 10 mg once daily with food in combination with clopidogrel (preferred P2Y12 inhibitor) is suggested based on trial design of PIONEER AF-PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959713'])">Ref</a></span>). <b>Note:</b> In the PIONEER AF-PCI study, a relatively small number of patients required this dose reduction. Upon completion of this rivaroxaban and clopidogrel regimen, patient should be transitioned to the recommended rivaroxaban dosing for nonvalvular atrial fibrillation.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Avoid use. These patients were excluded from the clinical trial for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959713'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute coronary syndrome (after stabilization with initial management) (off label): </b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥ 30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22077192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22077192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Avoid use; these patients were excluded from the clinical trial for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22077192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22077192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Coronary artery disease, stable:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥15 mL/minute: No dosage adjustment necessary; use with caution in severe impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Avoid use; patients with eGFR &lt;15 mL/minute were excluded from the clinical trial for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28844192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28844192'])">Ref</a></span>); currently, no other clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056'])">Ref</a></span>). The manufacturer provides conflicting recommendations in US and Canadian labeling. The US manufacturer's labeling does not recommend a dose adjustment in this population; however, this is based on a single-dose (10 mg) pharmacokinetic study that did not evaluate clinical outcomes. In contrast, the Canadian labeling recommends to avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Left ventricular thrombus (off label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Specific data in patients with kidney impairment are lacking; as most studies utilized dosing that is consistent with the nonvalvular atrial fibrillation indication, it may be reasonable to apply the same dosage adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral artery disease, stable:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥15 mL/minute: No dosage adjustment necessary; use with caution in severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Avoid use; patients with eGFR &lt;15 mL/minute were excluded from the clinical trial for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222135','lexi-content-ref-28844192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222135','lexi-content-ref-28844192'])">Ref</a></span>); currently, no other clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056'])">Ref</a></span>). The manufacturer provides conflicting recommendations in US and Canadian labeling. The US manufacturer's labeling does not recommend a dose adjustment in this population; however, this is based on a single-dose (10 mg) pharmacokinetic study that did not evaluate clinical outcomes. In contrast, the Canadian labeling recommends to avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Superficial vein thrombosis, acute symptomatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use; Patients with CrCl &lt;30 mL/minute were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219692'])">Ref</a></span>); no other clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<b>Deep vein thrombosis and/or pulmonary embolism treatment OR heparin-induced thrombocytopenia:</b></b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to &lt;30 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>). Patients with CrCl &lt;30 mL/minute were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21128814','lexi-content-ref-22449293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21128814','lexi-content-ref-22449293'])">Ref</a></span>); very limited clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056','lexi-content-ref-37115488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056','lexi-content-ref-37115488'])">Ref</a></span>). Manufacturer labeling recommends no dosage adjustment in patients with CrCl ≥15 mL/minute but acknowledges the limited clinical data, increased exposure, and increased pharmacodynamic effects compared to patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Indefinite anticoagulation (reduced intensity dosing against venous thromboembolism recurrence) OR </b>
<b>venous thromboembolism prophylaxis for acutely ill medical patients, nonmajor orthopedic surgery of lower limb, total hip arthroplasty or total knee arthroplasty:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to &lt;30 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>). Patients with CrCl &lt;30 mL/minute were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18579811','lexi-content-ref-18582928','lexi-content-ref-18579812','lexi-content-ref-32223113','lexi-content-ref-30145946','lexi-content-ref-19411100','lexi-content-ref-28316279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18579811','lexi-content-ref-18582928','lexi-content-ref-18579812','lexi-content-ref-32223113','lexi-content-ref-30145946','lexi-content-ref-19411100','lexi-content-ref-28316279'])">Ref</a></span>); very little clinical data are available to support use in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307056','lexi-content-ref-37115488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307056','lexi-content-ref-37115488'])">Ref</a></span>). Manufacturer labeling recommends no dosage adjustment in patients with CrCl ≥15 mL/minute but acknowledges the limited clinical data, increased exposure, and increased pharmacodynamic effects compared to patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25804678','lexi-content-ref-27100875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25804678','lexi-content-ref-27100875'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987686"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Clinical trials used to support the FDA-approved indications excluded patients with more severe hepatic impairment, and therefore, the manufacturer’s labeling recommends against use in patients with moderate to severe (Child-Turcotte-Pugh class B to C) hepatic impairment or with any hepatic disease associated with coagulopathy. Evidence to support use in liver insufficiency comes from postmarketing, primarily single-center, observational studies. Rivaroxaban is primarily metabolized in the liver (~65%). In a single-dose rivaroxaban pharmacokinetic study, total body clearance and renal clearance are reduced in Child-Turcotte-Pugh class B, leading to an increased AUC with no significant difference in Child-Turcotte-Pugh class A compared to healthy subjects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23294275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23294275'])">Ref</a></span>). Rivaroxaban is also highly albumin bound, and patients with low serum albumin levels have a higher free fraction of drug, which may increase risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23294275','lexi-content-ref-32279215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23294275','lexi-content-ref-32279215'])">Ref</a></span>). No pharmacokinetic data are available in severe hepatic impairment (Child-Turcotte-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">In patients with a higher bleeding risk, a direct oral anticoagulant, such as apixaban or dabigatran, with an approved antidote and/or more favorable pharmacokinetic profile should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35646264','lexi-content-ref-36571829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35646264','lexi-content-ref-36571829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>
<i></i></b>
<b>
<i></i></b>
<b>Rivaroxaban Initial or Dose Titration in Patients With Preexisting Liver Cirrhosis</b>
<b>
<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Indication</p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Child-Turcotte-Pugh class A</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Child-Turcotte-Pugh class B </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Child-Turcotte-Pugh class C</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>
<sup>a </sup></b>In general, use not recommended in patients with platelet count &lt;50,000/mm<sup>3</sup>, high-risk esophageal varices, or severe kidney impairment (ACG [Simonetto 2020]; Biolato 2022; Vandenberk 2023).</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b </sup>Majority of data is based on studies in patients with portal vein thrombosis.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>c</sup> Vandenberk 2023; Violi 2020.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>d </sup>Vandenberk 2023.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>e</sup> Expert opinion.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>f</sup> Urban 2019; expert opinion.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>g</sup> Bosch 2017; Eikelboom 2017; Mega 2012.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>h</sup> Bonaca 2020; Eikelboom 2017.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>i</sup> Beyer-Westendorf 2017.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>j</sup> Ballestri 2020; Biolato 2022; Potpara 2015.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>k</sup> Biolato 2022.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>l</sup> Ai 2020; Agnelli 2007<b>; </b>Hanafy 2019; Hum 2017; Jarboe 2022; Ilcewicz 2021; Intagliata 2016; Naymagon 2021; expert opinion.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>m</sup> Biolato 2022; Lamarche 2021.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>n</sup> Cohen 2013; Kakkar 2008; Lassen 2008; expert opinion.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Atrial fibrillation, nonvalvular</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use not recommended; use of other direct oral anticoagulant agents with a more favorable pharmacokinetic profile are generally preferred (eg, apixaban, dabigatran).<sup>d</sup> Additionally, use of rivaroxaban is not recommended if platelet count &lt;50,000/mm<sup>3</sup> and/or serum albumin &lt;3 g/dL.<sup>e</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use not recommended.<sup>e</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-percutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>e</sup></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Use not recommended; in general, patients with known hepatic disease considered severe or associated with coagulopathy were excluded from percutaneous coronary intervention clinical trials.<sup>f</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Coronary artery disease, stable</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Coronary artery disease (stable or acute coronary syndrome after stabilization with initial management)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>e</sup></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Use not recommended; patients with known hepatic disease considered severe or associated with coagulopathy were excluded from coronary artery disease clinical trials.<sup>g</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Heparin-induced thrombocytopenia</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Heparin-induced thrombocytopenia with and without thrombosis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>e</sup></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Use not recommended.<sup>e</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Peripheral artery disease, stable</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Peripheral artery disease, stable</p></td>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">Use not recommended; patients with known hepatic disease associated with coagulopathy were excluded from peripheral artery disease clinical trials.<sup>h</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Superficial vein thrombosis, acute symptomatic</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Superficial vein thrombosis, acute symptomatic</p></td>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">Use not recommended; patients with significant liver disease were excluded from superficial vein thrombosis clinical trials.<sup>i</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Venous thromboembolism</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Deep vein thrombosis and/or pulmonary embolism treatment<sup>b</sup></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p>
<p style="text-indent:0em;text-align:left;">
<b>
<i></i></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>j</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use of other direct oral anticoagulant agents with a more favorable pharmacokinetic profile in hepatic impairment are generally preferred (eg, apixaban, dabigatran).<sup>k</sup> If use of rivaroxaban deemed necessary, there are no specific dosage adjustments recommended (dose must be individualized); doses utilized in clinical trials varied considerably; use with extreme caution.<sup>l</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use not recommended.<sup>m</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Indefinite anticoagulation (reduced intensity dosing for prophylaxis against venous thromboembolism recurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>e</sup></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Use not recommended.<sup>e</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Venous thromboembolism prophylaxis, short-term use (eg, acutely ill medical patients, hip/knee arthroplasty)</p></td>
<td align="left" colspan="3">
<p style="text-indent:0em;">Use not recommended; patients with hepatic impairment were excluded from venous thromboembolism prophylaxis clinical trials.<sup>n</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage</b>
<b> adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression to Child-Turcotte-Pugh class A: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression to Child-Turcotte-Pugh class B and C:</b> Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization): </b>Discontinue rivaroxaban in patients with platelet count &lt;50,000/mm<sup>3</sup>, high-risk esophageal varices, or severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31895720','lexi-content-ref-35646264','lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31895720','lexi-content-ref-35646264','lexi-content-ref-expert.doh'])">Ref</a></span>) or in patients that progress from Child-Turcotte-Pugh class B to C (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34152697','lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34152697','lexi-content-ref-expert.doh'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54507360"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Major hemorrhage</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban may increase the risk of <b>hemorrhage,</b> including severe and potentially fatal <b>major</b>
<b>hemorrhage </b>as defined by the International Society on Thrombosis and Hemostasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19878532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19878532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; for anticoagulants in general, risk may be highest within 3 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20886196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20886196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Drug-specific</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">• Low serum albumin levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23294275','lexi-content-ref-32279215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23294275','lexi-content-ref-32279215'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>General </b> (any anticoagulant):</p>
<p style="text-indent:-2em;margin-left:8em;">• History of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of prior bleeding event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemostatic abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney or hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of drugs that affect hemostasis or interact to increase exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28973247','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28973247','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Nonwhite race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17659197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17659197'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Excessive fall risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Spinal or epidural hematomas</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal hematoma </b>or<b> epidural intracranial hemorrhage</b> may occur in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoing spinal puncture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958','lexi-content-ref-26379302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958','lexi-content-ref-26379302'])">Ref</a></span>); may result in long-term or permanent paralysis. Spontaneous spinal or epidural hematomas (SEH) have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26090890','lexi-content-ref-26228186','lexi-content-ref-29849242','lexi-content-ref-29079069','lexi-content-ref-21874549','lexi-content-ref-27088353','lexi-content-ref-26543654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26090890','lexi-content-ref-26228186','lexi-content-ref-29849242','lexi-content-ref-29079069','lexi-content-ref-21874549','lexi-content-ref-27088353','lexi-content-ref-26543654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>SEH due to neuraxial anesthesia or spinal puncture is related to trauma in the presence of impaired hemostasis with rivaroxaban. Spontaneous SEH may be due to sudden increases in thoracic and/or abdominal pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29670777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29670777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>SEH in patients treated with rivaroxaban who received neuraxial anesthesia or spinal puncture: Rapid; manifested within 48 hours following the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958','lexi-content-ref-26379302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958','lexi-content-ref-26379302'])">Ref</a></span>). Spontaneous SEH: Varied; case reports have occurred from 5 days to 3 years after rivaroxaban initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26090890','lexi-content-ref-26228186','lexi-content-ref-29849242','lexi-content-ref-29079069','lexi-content-ref-21874549','lexi-content-ref-27088353','lexi-content-ref-26543654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26090890','lexi-content-ref-26228186','lexi-content-ref-29849242','lexi-content-ref-29079069','lexi-content-ref-21874549','lexi-content-ref-27088353','lexi-content-ref-26543654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Use of indwelling epidural catheters</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant administration of other drugs that affect hemostasis (eg, aspirin, nonsteroidal anti-inflammatory drugs, platelet inhibitors, other anticoagulants)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of traumatic or repeated epidural or spinal punctures</p>
<p style="text-indent:-2em;margin-left:6em;">• History of spinal deformity or surgery</p>
<p style="text-indent:-2em;margin-left:6em;">• If optimal timing between administration of rivaroxaban and neuraxial procedures is unknown</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemostatic abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Epidural rather than spinal anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Challenging neuraxial procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for spontaneous SEH: Stretch exercises, Valsalva maneuvers, defecation, hypertension, structural extradural anomalies, and rupture of fragile epidural veins by an adjacent herniated disk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32351744','lexi-content-ref-Goyal.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32351744','lexi-content-ref-Goyal.2016'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F6724117"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise specified.</p>
<p style="text-indent:0em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:0em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding (adolescents: 27%)</p>
<p style="text-indent:0em;margin-left:4em;">Gastrointestinal: Gastroenteritis (pediatric patients: 13%), vomiting (pediatric patients: 11% to 14%)</p>
<p style="text-indent:0em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (pediatric patients and adults: 5% to 36%; major hemorrhage: ≤4%)<span class="lexi-table-link-container"> (<a aria-label="Major Hemorrhage table link" class="lexi-table-link" data-table-id="lexi-content-major-hemorrhage" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-major-hemorrhage')">table 1</a>)</span><span class="table-link" style="display:none;">Major Hemorrhage</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Major Hemorrhage" frame="border" id="lexi-content-major-hemorrhage" rules="all">
<caption style="text-align:center;">
<b>Rivaroxaban: Adverse Reaction: Major Hemorrhage</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivaroxaban)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivaroxaban)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Body weight-adjusted doses</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thromboprophylaxis in patients with congenital heart disease after the Fontan procedure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Aspirin</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Body weight-adjusted doses</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of venous thromboembolism and reduction in risk of recurrent venous thromboembolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">329</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Unfractionated heparin, low molecular weight heparin, fondaparinux, or vitamin K antagonist</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg or 20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nonvalvular atrial fibrillation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7,111</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7,125</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Warfarin</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prophylaxis of deep vein thrombosis following hip replacement surgery</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,281</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,298</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Enoxaparin</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prophylaxis of deep vein thrombosis following knee replacement surgery</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,206</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,226</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Enoxaparin</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prophylaxis of venous thromboembolism in acutely ill medical patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,218</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,229</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Enoxaparin/placebo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reduction in the risk of recurrence of deep vein thrombosis and/or pulmonary embolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,131</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Acetylsalicylic acid</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg twice daily for 3 weeks followed by 20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treatment of deep vein thrombosis and/or pulmonary embolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Enoxaparin/vitamin K antagonist</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (pediatric patients: 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%), skin blister (1%), skin rash (pediatric patients: 9%), wound secretion (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), gastrointestinal hemorrhage (2%)</p>
<p style="text-indent:0em;margin-left:2em;">Hepatic: Increased serum transaminases (&gt;3 x ULN: 2%) (Watkins 2011)</p>
<p style="text-indent:0em;margin-left:2em;">Nervous system: Anxiety (1%), depression (1%), dizziness (2%), fatigue (pediatric patients: 7%; adults: 1%), insomnia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%), limb pain (pediatric patients and adults: 2% to 7%), muscle spasm (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemophthalmos, surgical bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hemorrhagic stroke, intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade (Oladiran 2018), hemopericardium (Basnet 2017), thrombosis (with premature discontinuation) (Nagasayi 2017; Shaw 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Watras 2016), bullous pemphigoid (Ferreira 2018), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal hemorrhage (bilateral) (Alidoost 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Aslan 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding (Jacobson-Kelly 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, retroperitoneal hemorrhage (Börekci 2019), splenic rupture (Nagaraja 2018), thrombocytopenia (Mima 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Baig 2015), hepatic injury (Glenn 2017; Licata 2018), hepatitis (Russmann 2014), jaundice (Glenn 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Khan 2021), angioedema (Patil 2019), drug reaction with eosinophilia and systemic symptoms (Chiasson 2017), hypersensitivity angiitis (Lee 2019), hypersensitivity reaction (Wu 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage (Hagii 2014; Wilson 2016), epidural intracranial hemorrhage (Burjorjee 2018; Jaeger 2012), hemiparesis, spinal hematoma (Goldfine 2018; Madhisetti 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Vitreous hemorrhage (spontaneous) (Jun 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal disease</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiectasis, eosinophilic pneumonitis, pulmonary hemorrhage (Ciofoaia 2018; Hammar 2015)</p></div>
<div class="block coi drugH1Div" id="F6724113"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity to rivaroxaban or any component of the formulation; active pathological bleeding</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hepatic disease (including Child-Pugh classes B and C) associated with coagulopathy and clinically relevant bleeding risk; lesions or conditions at increased risk of clinically significant bleeding (eg, hemorrhagic or ischemic cerebral infarction, spontaneous or acquired impairment of hemostasis, active peptic ulcer disease with recent bleeding); concomitant systemic treatment with strong CYP3A4 and P-glycoprotein (P-gp) inhibitors (eg, cobicistat, ketoconazole, itraconazole, posaconazole, ritonavir); concomitant use with any other anticoagulant including unfractionated heparin (except at doses used to maintain central venous or arterial catheter patency), low molecular weight heparins (eg, enoxaparin, dalteparin) or heparin derivatives (eg, fondaparinux); concomitant use with warfarin, dabigatran, edoxaban, or apixaban except when switching therapy to or from rivaroxaban; pregnancy; lactation</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F6724114"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiphospholipid syndrome: Use not recommended in patients with triple-positive antiphospholipid syndrome; safety and efficacy have not been established. Patients positive for all 3 antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I) may have increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation (non-valvular): An increased rate of stroke was observed during the transition from rivaroxaban to warfarin in clinical trials in atrial fibrillation (AF) patients. In a post-hoc analysis of the ROCKET AF trial, patients who temporarily (&gt;3 days) or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban as compared to warfarin (Patel 2013). In patients with nonvalvular AF who had an acute ischemic stroke while receiving a direct-acting oral anticoagulant (DOAC) (eg, rivaroxaban), guidelines generally support withholding oral anticoagulation until 4 to 14 days after the onset of neurological symptoms (time frame may vary with shorter times for transient ischemic attack or small, nondisabling stroke and longer times for moderate to severe stroke) (AHA/ASA [Kernan 2014]; AHA/ASA [Powers 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI/Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Evaluate the risk versus benefit of possible decreased drug absorption. Rivaroxaban is significantly absorbed through the stomach. Procedures that reduce the absorptive surface area of the stomach or accelerate gastric emptying (eg, sleeve gastrectomy) may decrease bioavailability of rivaroxaban. A small study evaluating pre- and post-gastric restriction surgery showed a significant reduction in peak rivaroxaban levels (Rottenstreich 2018). Peak concentrations and AUC were reduced by 56% and 29%, respectively, when released into the proximal small intestine and further reduced in the distal small intestine or colon (manufacturer labeling 2019). The available data are conflicting for absorption alterations, derived from small populations, and underrepresent individual DOACs and distinct surgeries (Kröll 2017; Kröll 2018; Lee 2013; Rottenstreich 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Avoid use or use with caution in patients with existing hepatic impairment or with any hepatic disease associated with coagulopathy prior to initiation of rivaroxaban therapy. Management of patients established on rivaroxaban who experience acute or chronic worsening of hepatic function may vary depending on degree of dysfunction (eg, class A vs class C) and/or presence of risk factors (eg, low platelet count, esophageal varices).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Dose adjustment is necessary for patients with kidney impairment, and specific adjustments are indication specific. Discontinue use in patients who develop acute kidney failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Valvular disease: Avoid use in patients with surgically implanted mechanical heart valve, transcatheter aortic valve replacement with no other indication for anticoagulation, moderate to severe mitral stenosis, or significant rheumatic heart disease. However, may be used in patients with atrial fibrillation and native aortic valve disease, tricuspid valve disease, mitral regurgitation, or surgical bioprosthetic mitral valve replacement when anticoagulation is required (ACC/AHA [Otto 2021]; AHA/ACC/HRS [January 2014]; AHA/ACC/HRS (January 2019)]; Dangas 2020; Guimarães 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adult patients. Older patients exhibit higher rivaroxaban concentrations compared to younger patients due primarily to reduced clearance. Overall, efficacy of rivaroxaban in older patients (≥65 years of age) was similar to that of patients &lt;65 years of age. Both thrombotic and bleeding events were higher in older patients; however, the risk to benefit profile was favorable among all age groups.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Oral suspension contains sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose intolerance: May contain lactose; use is not recommended in patients with lactose or galactose intolerance (eg, congenital lactase deficiency, glucose-galactose malabsorption).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: When temporary interruption is necessary before surgery or a procedure, the timing of discontinuation depends on kidney function and risk for bleeding complications. In patients with CrCl ≥30 mL/minute, discontinue therapy ~24 to 48 hours before surgery, depending on risk for bleeding. In patients with CrCl &lt;30 mL/minute, may consider discontinuing therapy ~48 to 72 hours before surgery, depending on risk for bleeding. Consider discontinuing for a longer period of time in patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. After discontinuation, bridging with low molecular weight heparin or heparin perioperatively is not necessary and may increase risk of bleeding. When there is adequate hemostasis after surgery, may reinstitute therapy after ≥24 hours depending on risk for bleeding. Specific considerations can be found in expert scientific statements and consensus pathways (ACC [Doherty 2017]; ACCP [Douketis 2022]; AHA [Raval 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Spinal or epidural hematoma: Neuraxial intervention is best performed when the anticoagulant effect of rivaroxaban is low. Guidelines recommend discontinuation of rivaroxaban 72 hours prior to neuraxial intervention; if &lt;72 hours, consider checking anti-factor Xa level (Horlocker 2018). For unanticipated neuraxial intervention, guidelines recommend waiting at least 22 to 26 hours following the last rivaroxaban dose when using prophylactic dosing (eg, 10 mg once daily) before neuraxial puncture and/or catheter manipulation/withdrawal (Horlocker 2018). When higher doses are used (eg, &gt;10 mg once daily) and/or in patients with CrCl &lt;50 mL/minute, waiting 44 to 65 hours following the last rivaroxaban dose is recommended (Horlocker 2018; Rosencher 2013). Avoid rivaroxaban administration for at least 6 hours following neuraxial puncture or neuraxial catheter withdrawal; if traumatic puncture occurs, avoid rivaroxaban administration for at least 24 hours. In addition to these and other clinical variables, consider kidney function and the age of the patient (elderly patients exhibit a prolonged rivaroxaban half-life [11 to 13 hours]) (Kubitza 2010; Rosencher 2013). The Canadian labeling recommends avoiding doses &gt;10 mg in patients with a postoperative indwelling epidural catheter.</p></div>
<div class="block foc drugH1Div" id="F13107817"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xarelto: 1 mg/mL (155 mL) [contains sodium benzoate; sweet flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xarelto: 2.5 mg, 10 mg, 15 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xarelto Starter Pack: 15 mg (42s) and 20 mg (9s) (51 ea)</p></div>
<div class="block geq drugH1Div" id="F20452764"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321848"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Xarelto Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Xarelto Starter Pack Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 &amp; 20 mg (per each): $21.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xarelto Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $10.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $21.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $21.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $21.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868974"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xarelto: 1 mg/mL (100 mL, 250 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xarelto: 2.5 mg, 10 mg, 15 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 10 mg, 15 mg, 20 mg</p></div>
<div class="block admp drugH1Div" id="F54282222"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with feeding or food when used to treat venous thromboembolism (VTE). Administer with or without food when used for thromboprophylaxis after Fontan procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: May be administered by mouth or via nasogastric/gastric feeding tube. For nasogastric/gastric feeding tube administration, flush tube with water after administration. If treating or reducing risk of VTE, follow dose immediately by enteral feeding.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Swallow tablets whole; do not split tablets. <b>Note:</b> Rivaroxaban 2.5 mg tablets are not recommended for use in pediatric patients; safety, efficacy, and pharmacokinetic/pharmacodynamic data are lacking for this dosage form. For pediatric patients who cannot swallow the 10 mg, 15 mg, or 20 mg tablet whole, transition to oral suspension. In adults unable to swallow tablets whole, crushing tablets and mixing with applesauce immediately prior to use is recommended; administer within 4 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:6em;">For nasogastric/gastric feeding tube administration, the tablets may be crushed and mixed in 50 mL of water; administer the suspension within 4 hours of preparation. Avoid administration distal to the stomach; a decrease in the AUC and C<sub>max</sub> was observed when rivaroxaban was delivered to the proximal small intestine; further decreases may be seen with delivery to the distal small intestine or ascending colon.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Once-daily dosing: Administer missed dose as soon as possible on the same day. If it is not possible to administer on the same day, skip dose and take next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Twice-daily dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Missed morning dose: Administer missed morning dose as soon as possible; may take missed dose with evening dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Missed evening dose: Administer missed evening dose as soon as possible in the same evening. If it is not possible to take in the same evening, skip dose and take next scheduled dose in the morning. <b>Note: </b>A missed evening dose can only be taken in the same evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Three-times-a-day dosing: Skip missed dose and take next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Vomit or spit up: Administer another dose if vomiting or spit up occurs within 30 minutes of receiving dose. If vomiting occurs &gt;30 minutes after dose is administered, do not repeat; administer next scheduled dose.</p></div>
<div class="block adm drugH1Div" id="F6724172"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer doses ≥15 mg with food; doses of 2.5 mg and 10 mg may be administered without regard to meals. For nonvalvular atrial fibrillation, administer with the evening meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Only use oral dosing syringes provided. May be administered via nasogastric/gastric feeding tube; flush feeding tube with water after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: For patients who cannot swallow whole tablets, the tablets may be crushed and mixed with applesauce immediately prior to use; immediately follow administration of the 15 mg and 20 mg tablets with food (2.5 mg and 10 mg tablets may be administered without regard to food).</p>
<p style="text-indent:-2em;margin-left:4em;">For nasogastric/gastric feeding tube administration, the tablets may be crushed and mixed in 50 mL of water; administer the suspension within 4 hours of preparation and follow administration of the 15 mg and 20 mg tablets immediately with enteral feeding (2.5 mg and 10 mg tablets may be administered without regard to food). Avoid administration distal to the stomach; a decrease in the AUC and C<sub>max</sub> (29% and 56%, respectively) was observed when rivaroxaban was delivered to the proximal small intestine; further decreases may be seen with delivery to the distal small intestine or ascending colon.</p>
<p style="text-indent:0em;margin-top:2em;">Missed doses: Patients receiving 15 mg twice daily dosing who miss a dose should take a dose immediately to ensure 30 mg of rivaroxaban is administered per day (two 15 mg tablets may be taken together); resume therapy the following day as previously taken. Patients receiving 2.5 mg twice daily who miss a dose should take a single 2.5 mg dose at the next scheduled time; then resume therapy as usual. Patients receiving once-daily dosing who miss a dose should take a dose as soon as possible on the same day; resume therapy the following day as previously taken.</p></div>
<div class="block sts drugH1Div" id="F6724144"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze granules or reconstituted suspension. After preparation, use suspension within 60 days.</p></div>
<div class="block meg drugH1Div" id="F13376301"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022406s039%2C202439s038lbl.pdf%23page%3D77&amp;token=wccInHilr4WbXJdgkk4mcCVLQMwnm%2FBtn4gcCPE0E4dpLkp9Fr8QKWnNixtJtGUr83FFm7%2FzlJcFGI32ltd0Na5TAmPiQ0MCDqwkRkA9Q63pWCrdSsOIfITSzYcyXqDK&amp;TOPIC_ID=127822" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022406s039,202439s038lbl.pdf#page=77</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570311"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of venous thromboembolism (VTE) after ≥5 days of initial treatment with a parenteral anticoagulant (FDA approved in ages &lt;18 years of age); reduce risk of recurrent VTE after ≥5 days of initial treatment with a parenteral anticoagulant (FDA approved in ages &lt;18 years of age); thromboprophylaxis in patients with congenital heart disease following the Fontan procedure (FDA approved in pediatric patients ≥2 years of age); reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (FDA approved in adults); treatment of deep vein thrombosis (DVT) (FDA approved in adults); treatment of pulmonary embolism (PE) (FDA approved in adults); reduce risk of recurrent DVT and/or PE in patients at continued risk after completing at least 6 months of initial treatment (FDA approved in adults); prophylaxis of DVT in patients undergoing knee or hip replacement surgery; prophylaxis of VTE in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding (FDA approved in adults); reduce risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease (in combination with aspirin) (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F14199109"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, kidney function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Rivaroxaban is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) for long-term treatment of VTE or atrial fibrillation due to an increased risk of major bleeding and GI bleeding compared to safer alternatives for anticoagulation. Use may be reasonable in certain situations (eg, when once-daily dosing is necessary for medication adherence) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9838498"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP2J2 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6754126"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Rivaroxaban. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: May enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Rivaroxaban. Management: Consider alternatives to use of rivaroxaban with strong CYP3A4 inducers. Use of a strong CYP3A4 inducer with rivaroxaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein.  For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Rivaroxaban.  For clarithromycin, refer to more specific clarithromycin-rivaroxaban monograph recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of Rivaroxaban. Management: Consider alternatives to this combination when possible.  Rivaroxaban dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of CYP3A4 (Moderate) and P-glycoprotein: May decrease the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Moderate) and P-glycoprotein: May increase the serum concentration of Rivaroxaban. Management: No action is needed in patients with normal renal function. Do not use this combination in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Rivaroxaban. Management: No action is needed in patients with normal renal function. Do not use this combination in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May decrease the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May decrease the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May diminish the therapeutic effect of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53241207"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Clinically significant uterine bleeding requiring surgical intervention may occur during therapy in patients of reproductive potential.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of direct acting oral anticoagulants in pregnancy is limited; until safety data are available, adequate contraception is recommended during therapy for patients who may become pregnant. Patients planning to become pregnant should be switched to alternative anticoagulants prior to conception (Cohen 2016).</p></div>
<div class="block pri drugH1Div" id="F6724110"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on ex vivo data, rivaroxaban crosses the placenta (Bapat 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of rivaroxaban during pregnancy (Beyer-Westendorf 2016; Hoeltzenbein 2015; Königsbrügge 2014; Lameijer 2018; Myers 2016) and postpartum (Rudd 2015) is limited. Use of direct acting oral anticoagulants increases the risk of bleeding in all patients. When used in pregnancy, there is also the potential for fetal bleeding or subclinical placental bleeding which may increase the risk of miscarriage, preterm delivery, fetal compromise, or stillbirth (Cohen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Data are insufficient to evaluate the safety of direct acting oral anticoagulants during pregnancy and use in pregnant patients is not recommended (ACOG 2018; Regitz-Zagrosek [ESC 2018]). Agents other than rivaroxaban are preferred for the treatment of AF or VTE in pregnant patients (Kearon 2016; Lip 2018; Regitz-Zagrosek [ESC 2018]). Patients should be switched to an alternative anticoagulant if pregnancy occurs during therapy. Fetal monitoring that includes evaluations for fetal bleeding and assessments for risk of preterm delivery are recommended if the direct acting oral anticoagulant is continued (Cohen 2016).</p></div>
<div class="block mopp drugH1Div" id="F53570310"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential; renal function prior to initiation and when clinically indicated; hepatic function prior to initiation and when clinically indicated; stool occult blood tests, active bleeding. Monitoring for the anticoagulation effect of rivaroxaban using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not recommended by the manufacturer.</p></div>
<div class="block pha drugH1Div" id="F6724165"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa) in both the intrinsic and extrinsic coagulation pathways. FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, factor II and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin.</p></div>
<div class="block phk drugH1Div" id="F6724145"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; <b>Note:</b> Absorption dependent upon site of drug release; AUC was decreased by 29% and C<sub>max</sub> reduced by 56% when released in proximal small intestine, it is reduced further when released in distal small intestine or ascending colon.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~50 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~92% to 95% (primarily to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4/5 and CYP2J2.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Absolute bioavailability: 2.5 mg and 10 mg dose: ~80% to 100%; 20 mg dose: ~66% (fasting; increased with food).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric (Young 2020; manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;6 months: 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;2 years: 1.9 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years: 3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 4.2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: Terminal: 5 to 9 hours; Elderly: 11 to 13 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents: Median: 1.5 to 2.2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (66% primarily via active tubular secretion [~36% as unchanged drug; 30% as inactive metabolites]); feces (28% [7% as unchanged drug; 21% as inactive metabolites]).</p></div>
<div class="block phksp drugH1Div" id="F51159802"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Rivaroxaban exposure is increased by a mean 44% in patients with mild impairment (CrCl 50 to 79 mL/minute), 52% in patients with moderate impairment (CrCl 30 to 49 mL/minute), and 64% in patients with severe impairment (CrCl &lt;30 mL/minute). In patients with moderate kidney impairment, a 1.86-fold increase in the AUC for factor Xa inhibition and a 2.16-fold increase in PT prolongation was observed compared to patients with normal kidney function. In patients with severe kidney impairment, a 2-fold increase in the AUC for factor Xa inhibition and a 2.44-fold increase in PT prolongation was observed (Kubitza 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Significant increases in rivaroxaban exposure were observed in subjects with moderate hepatic impairment (Child-Turcotte-Pugh class B). Increases in pharmacodynamic effects were also observed. In a single-dose rivaroxaban pharmacokinetic study, total body clearance and renal clearance are reduced in Child-Turcotte-Pugh class B, leading to an increased AUC with no significant difference in Child-Turcotte-Pugh class A compared to healthy subjects (Kubitza 2013). No clinical data are available for patients with severe hepatic impairment (Child-Turcotte-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Bodyweight-adjusted dosing regimen matches exposure range in adults &lt;45 years of age treated with rivaroxaban 20 mg once daily (Male 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elderly patients exhibit higher plasma concentrations than younger patients, with mean AUC values being ~50% higher, mainly because of reduced (apparent) total body and renal clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Healthy Japanese subjects were found to have 20% to 40% higher exposures compared with other ethnicities, including Chinese subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961940"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Abaxon | Antitrom | Drinax r | Remexal | Remivox | Rivacrist | Rixatyl | Xarelto | Xaroban</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Kinexa | Oxaban | Rivaxa | Roxarel | Varox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acog | Dacxi | Faxxa | Rivacrist | Rivaroxabana | Rivaroxabana cimed | Rivaroxabana eurofarma | Rivaroxabana neo quimica | Rivaroxabana pharlab | Rivaroxabana uniao quimica | Rivaxa | Rivneo | Rixantil | Varoxred | Vynaxa | Xafac | Xarelto</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Xarelto | Xarelto vascular</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rilex | Rivoxa | Trombex | Xarelto</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An ri xin | Jin kang | Xarelto</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Varoxred | Xarelto</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Rivoxa | Xarelto | Xaroban</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andorivaban | Eliproxaban | Orgoroxaban | Repatoxaban | Rivarospire | Rivaxarelt | Vaxato | Xanoxiban | Xarelto</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nostrok | Xarelto</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acriban | Alriza | Axcelto | Cameriv | Exafib | Flovas | Ifaxa | Ixarola | Rebless | Ricosprin | Rivaban | Rivaclot | Rivaflo | Rivalto | Rivared | Rivatane | Rivatop | Rivatroy | Rivaxa | Rivaxon | Rivazest | Rivolas | Rivoxamac | Rixant | Rixavin | Rovor | Rpigat | Rrb | Thrombonex | Unclot | Viklot | Xarelto | Xarex | Xarocad | Xavian | Zeroclot</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Rexova | Xarelto | Zarlan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Riroxator | Roxalto | Varoxa | Vaxato | Xarelto | Xiona</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahngook new pharm rivaroxaban | Ahngook rivaroxaban | Aroxaban | Azarel | Daihan rivaroxaban | Diroxaban | Dongkoo rivaroxaban | Hanwha rivaroxaban | Ibarok | Ilsung rivaroxaban | Jatol | Javato | Jrelto | Kukje rivaroxaban | Libantil | Myungin rivaroxaban | Ribarocto | Ribaxan | Rinello | Rinelto | Rirelto | Riroxaban | Riroxban | Riroxia | Rivacor | Rivakxaban | Rivarel | Rivarflo | Rivaroc | Rivarogen | Rivarok m | Rivarol | Rivarot | Rivarox | Rivaroxin | Rivavel | Rivaxaban | Rivoroxa | Rivoxaban | Rivoxavan | Roxaone | Sk rivaroxaban | Wirelto | Xabarelto | Xaito | Xanet | Xarelb | Xareliban | Xarelro | Xarelson | Xarelto | Xarexaban | Xarox | Xaroxaban | Xaroxte | Yooroxaban | Yuvaro | Zarel Q</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ribavan | Rixalta | Xarelto | Xaviran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Rexaban | Xarelto</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Loventrax | Tirevin | Xarelto</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lixavan | Plaxaban | Xarelto</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arixa | Baroxa | Mabinat | Nabaxo | Neurivox | Novaclop plus | Oxaban | Raxelto | Revoban | Ribax | Ricoag | Ritban | Rivaban | Rivaclot | Rivaplat | Rivar | Rivaro | Rivarox | Rivascot | Rivaxa | Rivaxo | Rivoban | Rivox | Rivroxa | Roban | Roxab | Roxaban | Roxalis | Valoxaban | Vaxato | Xalia | Xarelto | Xaremit | Xaroban | Xavarox | Xcept | Xiona | Xoxiban</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Xarelto | Xavir</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Banoriv | Rivaroxaban spc | Taburex | Varoxa | Xarelto</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Assubex | Rivaroxaban sandoz | Rivaxa | Xanirva | Xarelto | Xerdoxo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rivarox | Rivoxan | Xarelto</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Riva | Xaban | Xarelto</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rivoksar | Voxaban | Xarelto</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ribex | Rivarox | Roxaban | Xarelto | Xaroban</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arudil | Asarap | Xarelto</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Langitax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ixarola | Rezalto | Rivar | Rivaroxaban accord | Rivaroxaban adco | Rivaroxaban teva | Rivaxored | Rivoxa | Varoxo | Xafariv | Xarelto</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Xarelto</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27574712">
<a name="27574712"></a>Abayon M, Kolokythas A, Harrison S, Elad S. Dental management of patients on direct oral anticoagulants: Case series and literature review. <i>Quintessence Int</i>. 2016:47(8):687-696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27574712/pubmed" id="27574712" target="_blank">27574712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33766266">
<a name="33766266"></a>Abdelnabi M, Saleh Y, Fareed A, et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). <i>J Am Coll Cardiol.</i> 2021;77(12):1590-1592. doi:10.1016/j.jacc.2021.01.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33766266/pubmed" id="33766266" target="_blank">33766266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32675774">
<a name="32675774"></a>Ai MH, Dong WG, Tan XP, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. <i>Eur J Gastroenterol Hepatol</i>. 2020;32(10):1395-1400. doi:10.1097/MEG.0000000000001846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32675774/pubmed" id="32675774" target="_blank">32675774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31676747">
<a name="31676747"></a>Alidoost M, Soomro R, Gubeladze A, et al. Rivaroxaban related bilateral adrenal hemorrhage: A rare complications of direct oral anticoagulants - a case reports. <i>Am J Case Rep</i>. 2019;20:1607-1611. doi:10.12659/AJCR.917780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31676747/pubmed" id="31676747" target="_blank">31676747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29466159">
<a name="29466159"></a>Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty.<i> N Engl J Med. </i>2018;378(8):699-707. doi:10.1056/NEJMoa1712746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29466159/pubmed" id="29466159" target="_blank">29466159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17576867">
<a name="17576867"></a>Agnelli G, Gallus A, Goldhaber SZ, et al; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. <i>Circulation</i>. 2007;116(2):180-187. doi:10.1161/CIRCULATIONAHA.106.668020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/17576867/pubmed" id="17576867" target="_blank">17576867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27669125">
<a name="27669125"></a>Arachchillage D, Reynolds R, Devey T, Maclean R, Kitchen S, van Veen JJ. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. <i>Thromb Res</i>. 2016;147:32-35. doi:10.1016/j.thromres.2016.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27669125/pubmed" id="27669125" target="_blank">27669125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26569514">
<a name="26569514"></a>Aslan AN, Sari C, Baştuğ S, et al. Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. <i>Blood Coagul Fibrinolysis</i>. 2016;27(2):226-227. doi:10.1097/MBC.0000000000000442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26569514/pubmed" id="26569514" target="_blank">26569514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi:10.1111/j.1538-7836.2012.04662.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26605205">
<a name="26605205"></a>Baig M, Wool KJ, Halanych JH, Sarmad RA. Acute liver failure after Initiation of rivaroxaban: a case report and review of the literature. <i>N Am J Med Sci</i>. 2015;7(9):407-410. doi:10.4103/1947-2714.166221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26605205/pubmed" id="26605205" target="_blank">26605205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28477860">
<a name="28477860"></a>Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial). <i>Am J Cardiol</i>. 2017;119(12):1989-1996. doi:10.1016/j.amjcard.2017.03.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28477860/pubmed" id="28477860" target="_blank">28477860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32285340">
<a name="32285340"></a>Ballestri S, Capitelli M, Fontana MC, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. <i>Adv Ther</i>. 2020;37(5):1910-1932. doi:10.1007/s12325-020-01307-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32285340/pubmed" id="32285340" target="_blank">32285340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26164691">
<a name="26164691"></a>Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. <i>Am J Obstet Gynecol</i>. 2015;213(5):710.e1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26164691/pubmed" id="26164691" target="_blank">26164691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28480082">
<a name="28480082"></a>Basnet S, Tachamo N, Tharu B, Dhital R, Ghimire S, Poudel DR. Life-threatening hemopericardium associated with rivaroxaban. <i>Case Rep Cardiol</i>. 2017;2017:4691325. doi:10.1155/2017/4691325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28480082/pubmed" id="28480082" target="_blank">28480082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30983472">
<a name="30983472"></a>Berger K, Santibañez M, Lin L, Lesch CA. A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage [published online ahead of print, 2019 Apr 14]. <i>J Intensive Care Med</i>. 2019;885066619840992. doi:10.1177/0885066619840992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30983472/pubmed" id="30983472" target="_blank">30983472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28743779">
<a name="28743779"></a>Bethea BT, Elliot JW, Richardson JB, Ahmed MI. Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia. <i>Am J Health Syst Pharm</i>. 2017;74(15):1153-1157. doi:10.2146/ajhp160368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28743779/pubmed" id="28743779" target="_blank">28743779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27384740">
<a name="27384740"></a>Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thromb Haemost</i>. 2016;116(4):651-658. doi:10.1160/TH16-04-0305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27384740/pubmed" id="27384740" target="_blank">27384740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219692">
<a name="28219692"></a>Beyer-Westendorf J, Schellong SM, Gerlach H, et al; SURPRISE investigators. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematol.</i> 2017;4(3):e105-e113. doi:10.1016/S2352-3026(17)30014-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28219692/pubmed" id="28219692" target="_blank">28219692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9727814">
<a name="9727814"></a>Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. <i>Am J Med</i>. 1998;105(2):91-99. doi:10.1016/s0002-9343(98)00198-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/9727814/pubmed" id="9727814" target="_blank">9727814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35646264">
<a name="35646264"></a>Biolato M, Paratore M, Di Gialleonardo L, Marrone G, Grieco A. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: what is the evidence? <i>World J Hepatol</i>. 2022;14(4):682-695. doi:10.4254/wjh.v14.i4.682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35646264/pubmed" id="35646264" target="_blank">35646264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20505955">
<a name="20505955"></a>Boer DP, de Rijke YB, Hop WC, Cransberg K, Dorresteijn EM. Reference values for serum creatinine in children younger than 1 year of age. <i>Pediatr Nephrol</i>. 2010;25(10):2107-2113. doi:10.1007/s00467-010-1533-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/20505955/pubmed" id="20505955" target="_blank">20505955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32222135">
<a name="32222135"></a>Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. <i>N Engl J Med</i>. 2020;382(21):1994-2004. doi:10.1056/NEJMoa2000052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32222135/pubmed" id="32222135" target="_blank">32222135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31656515">
<a name="31656515"></a>Börekci E. Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report. <i>Afr Health Sci</i>. 2019;19(2):2290-2293. doi:10.4314/ahs.v19i2.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31656515/pubmed" id="31656515" target="_blank">31656515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28754388">
<a name="28754388"></a>Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Can J Cardiol</i>. 2017;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28754388/pubmed" id="28754388" target="_blank">28754388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29369958">
<a name="29369958"></a>Burjorjee JE, Rooney R, Jaeger M. Epidural hematoma following cessation of a direct oral anticoagulant: a case report. <i>Reg Anesth Pain Med</i>. 2018;43(3):313-316. doi:10.1097/AAP.0000000000000738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29369958/pubmed" id="29369958" target="_blank">29369958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26090890">
<a name="26090890"></a>Castillo JM, Afanador HF, Manjarrez E, Morales XA. Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban. <i>Am J Case Rep</i>. 2015;16:377-381. doi:10.12659/AJCR.893320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26090890/pubmed" id="26090890" target="_blank">26090890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25595139">
<a name="25595139"></a>Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. <i>Circulation</i>. 2015;131(11):972-979. doi:10.1161/CIRCULATIONAHA.114.014113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25595139/pubmed" id="25595139" target="_blank">25595139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28973247">
<a name="28973247"></a>Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. doi:10.1001/jama.2017.13883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28973247/pubmed" id="28973247" target="_blank">28973247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35383658">
<a name="35383658"></a>Chen Y, Zhu M, Wang K, Xu Q, Ma J. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombus: an updated meta-analysis of cohort studies and randomized controlled trials. <i>J Cardiovasc Pharmacol</i>. 2022;79(6):935-940. doi:10.1097/FJC.0000000000001270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35383658/pubmed" id="35383658" target="_blank">35383658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28894315">
<a name="28894315"></a>Chiasson CO, Canneva A, Roy FO, Doré M. Rivaroxaban-induced hypersensitivity syndrome. <i>Can J Hosp Pharm</i>. 2017;70(4):301-304. doi:10.4212/cjhp.v70i4.1681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28894315/pubmed" id="28894315" target="_blank">28894315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ciofoaia.2018">
<a name="Ciofoaia.2018"></a>Ciofoaia G, Bilal TCM, Latef T. Rivaroxaban-induced diffuse alveolar damage. <i>Chest Journal</i>. 2018;405A. doi:10.1016/j.chest.2018.08.372</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23388003">
<a name="23388003"></a>Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>N Engl J Med</i>. 2013;368(6):513-523. doi:10.1056/NEJMoa1111096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/23388003/pubmed" id="23388003" target="_blank">23388003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27346676">
<a name="27346676"></a>Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(8):1673-1676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27346676/pubmed" id="27346676" target="_blank">27346676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29670777">
<a name="29670777"></a>Colell A, Arboix A, Caiazzo F, Grivé E. Iatrogenic spinal subdural hematoma due to apixaban: a case report and review of the literature. <i>Case Rep Hematol</i>. 2018;2018:4507638. doi:10.1155/2018/4507638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29670777/pubmed" id="29670777" target="_blank">29670777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31054829">
<a name="31054829"></a>Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. <i>Am J Med</i>. 2019;132(9):1078-1083. doi:10.1016/j.amjmed.2019.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31054829/pubmed" id="31054829" target="_blank">31054829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27983747">
<a name="27983747"></a>Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. <i>Pharmacotherapy</i>. 2017;37(2):236-248. doi:10.1002/phar.1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27983747/pubmed" id="27983747" target="_blank">27983747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31968126">
<a name="31968126"></a>Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. <i>Pharmacotherapy</i>. 2020;40(3):204-210. doi:10.1002/phar.2369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31968126/pubmed" id="31968126" target="_blank">31968126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32347755">
<a name="32347755"></a>Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Curr Med Res Opin</i>. 2020;36(7):1081-1088. doi:10.1080/03007995.2020.1762554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32347755/pubmed" id="32347755" target="_blank">32347755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coutre.2018">
<a name="Coutre.2018"></a>Crowther M. Management of heparin-induced thrombocytopenia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28316277">
<a name="28316277"></a>Crowther MA, Cuker A. Reduced-intensity rivaroxaban for the prevention of recurrent venous thromboembolism. <i>N Engl J Med</i>. 2017;376(13):1279-1280. doi:10.1056/NEJMe1701628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28316277/pubmed" id="28316277" target="_blank">28316277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv</i>. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuker.1">
<a name="Cuker.1"></a>Cuker A, Peyvandi F. Coronavirus disease 2019 (COVID-19): hypercoagulability. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dager.1">
<a name="Dager.1"></a>Dager WE, Gulseth MP, Nutescu EA, eds. <i>Anticoagulation Therapy: A Clinical Practice Guide.</i> 2nd ed. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31733180">
<a name="31733180"></a>Dangas GD, Tijssen JGP, Wöhrle J, et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. <i>N Engl J Med</i>. 2020;382(2):120-129. doi:10.1056/NEJMoa1911425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31733180/pubmed" id="31733180" target="_blank">31733180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228186">
<a name="26228186"></a>Dargazanli C, Lonjon N, Gras-Combe G. Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management. <i>Eur Spine J</i>. 2016;25 suppl 1:100-103. doi:10.1007/s00586-015-4160-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26228186/pubmed" id="26228186" target="_blank">26228186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28672052">
<a name="28672052"></a>Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. <i>Eur J Haematol</i>. 2017;99(4):332-335. doi:10.1111/ejh.12921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28672052/pubmed" id="28672052" target="_blank">28672052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25804678">
<a name="25804678"></a>De Vriese AS, Caluwé R, Bailleul E, et al. Dose-finding study of rivaroxaban in hemodialysis patients. <i>Am J Kidney Dis</i>. 2015;66(1):91-98. doi:10.1053/j.ajkd.2015.01.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25804678/pubmed" id="25804678" target="_blank">25804678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27100875">
<a name="27100875"></a>Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. <i>Am J Nephrol</i>. 2016;43(4):229-236. doi:10.1159/000445328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27100875/pubmed" id="27100875" target="_blank">27100875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081965">
<a name="28081965"></a>Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. <i>J Am Coll Cardiol</i>. 2017;69(7):871-898. doi:10.1016/j.jacc.2016.11.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28081965/pubmed" id="28081965" target="_blank">28081965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2019">
<a name="Pai.2019"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.2020">
<a name="Pai.2020"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 21, 2022a.</div>
</li>
<li>
<div class="reference">
                  Douketis JD, Mithoowani S. Prevention of venous thromboembolism (VTE) in adults undergoing non-major extremity orthopedic surgery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. December 21, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022c;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28844192">
<a name="28844192"></a>Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. <i>N Engl J Med</i>. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28844192/pubmed" id="28844192" target="_blank">28844192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29576106">
<a name="29576106"></a>Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>Br J Anaesth</i>. 2018;120(4):645-656. doi:10.1016/j.bja.2017.11.082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29576106/pubmed" id="29576106" target="_blank">29576106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11454370">
<a name="11454370"></a>Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet</i>. 2001;358(9275):9-15. doi:10.1016/S0140-6736(00)05249-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/11454370/pubmed" id="11454370" target="_blank">11454370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21128814">
<a name="21128814"></a>EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <i>N Engl J Med.</i> 2010;363(26):2499-2510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21128814/pubmed" id="21128814" target="_blank">21128814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22449293">
<a name="22449293"></a>EINSTEIN-PE Investigators; Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>N Engl J Med.</i> 2012;366(14):1287-1297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22449293/pubmed" id="22449293" target="_blank">22449293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32351744">
<a name="32351744"></a>El Alayli A, Neelakandan L, Krayem H. Spontaneous spinal epidural hematoma in a patient on apixaban for nonvalvular atrial fibrillation. <i>Case Rep Hematol</i>. 2020;2020:7419050. doi:10.1155/2020/7419050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32351744/pubmed" id="32351744" target="_blank">32351744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18579811">
<a name="18579811"></a>Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 study group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. <i>N Engl J Med.</i> 2008;358(26):2765-2775. doi:10.1056/NEJMoa0800374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/18579811/pubmed" id="18579811" target="_blank">18579811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36258660">
<a name="36258660"></a>Erstad BL, Barletta JF. Dilemmas related to direct-acting oral anticoagulant administration in patients with extreme obesity. <i>Ann Pharmacother.</i> 2023;57(6):727-737. doi:10.1177/10600280221130456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/36258660/pubmed" id="36258660" target="_blank">36258660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.doh">
<a name="expert.doh"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):S278-S325. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757117">
<a name="21757117"></a>Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. <i>J Am Coll Cardiol</i>. 2011;58(4):395-401. doi:10.1016/j.jacc.2011.03.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21757117/pubmed" id="21757117" target="_blank">21757117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27919873">
<a name="27919873"></a>Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. <i>Am J Health Syst Pharm</i>. 2016;73(24):2037-2041. doi:10.2146/ajhp150596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27919873/pubmed" id="27919873" target="_blank">27919873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30756013">
<a name="30756013"></a>Ferreira C, Oliveira A, Furtado A, Rocha N, Ribeiro JA. Bullous pemphigoid-like skin eruption during treatment with rivaroxaban: a clinical case study. <i>Eur J Case Rep Intern Med</i>. 2018;5(3):000724. Published 2018 Mar 21. doi:10.12890/2018_000724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30756013/pubmed" id="30756013" target="_blank">30756013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Frost C, et al. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. <i>Clin Pharmacol Drug Dev</i>. 2013;2(1):19.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16504638">
<a name="16504638"></a>Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).<i> Am Heart J</i>. 2006;151(3):713-719. doi:10.1016/j.ahj.2005.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/16504638/pubmed" id="16504638" target="_blank">16504638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20886196">
<a name="20886196"></a>Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. <i>Thromb Haemost</i>. 2010;104(6):1099-1105. doi:10.1160/TH10-07-0491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/20886196/pubmed" id="20886196" target="_blank">20886196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959713">
<a name="27959713"></a>Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. <i>N Engl J Med</i>. 2016;375(25):2423-2434. doi:10.1056/NEJMoa1611594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27959713/pubmed" id="27959713" target="_blank">27959713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28250999">
<a name="28250999"></a>Glenn K, Chen P, Musleh M, Pallivi R, Grilliot M. A rare case of rivaroxaban causing delayed symptomatic hepatocellular injury and hyperbilirubinemia. <i>Case Rep Gastrointest Med</i>. 2017;2017:5678187. doi:10.1155/2017/5678187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28250999/pubmed" id="28250999" target="_blank">28250999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20890208">
<a name="20890208"></a>Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM; European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <i>Eur J Anaesthesiol</i>. 2010;27(12):999-1015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/20890208/pubmed" id="20890208" target="_blank">20890208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29849242">
<a name="29849242"></a>Goldfine C, Glazer C, Ratzan RM. Spontaneous spinal epidural hematoma from rivaroxaban. <i>Clin Pract Cases Emerg Med</i>. 2018;2(2):151-154. doi:10.5811/cpcem.2018.2.37096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29849242/pubmed" id="29849242" target="_blank">29849242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29433148">
<a name="29433148"></a>Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. <i>Thromb Haemost</i>. 2018;118(3):437-450. doi:10.1055/s-0038-1627480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29433148/pubmed" id="29433148" target="_blank">29433148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goyal.2016">
<a name="Goyal.2016"></a>Goyal G, Singh R, Raj K. Anticoagulant induced spontaneous spinal epidural hematoma, conservative management or surgical intervention--a dilemma? <i>Journal of Acute Medicine</i>. 2016;38-42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33196155">
<a name="33196155"></a>Guimarães HP, Lopes RD, de Barros E Silva PGM, et al; RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. <i>N Engl J Med.</i> 2020;383(22):2117-2126. doi:10.1056/NEJMoa2029603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33196155/pubmed" id="33196155" target="_blank">33196155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31307056">
<a name="31307056"></a>Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. <i>Ann Intern Med.</i> 2019;171(3):181-189. doi:10.7326/M19-0087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31307056/pubmed" id="31307056" target="_blank">31307056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25082810">
<a name="25082810"></a>Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. <i>Stroke</i>. 2014;45(9):2805-2807. doi:10.1161/STROKEAHA.114.006661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25082810/pubmed" id="25082810" target="_blank">25082810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28050755">
<a name="28050755"></a>Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). <i>J Thromb Thrombolysis</i>. 2017;43(3):343-351. doi:10.1007/s11239-016-1465-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28050755/pubmed" id="28050755" target="_blank">28050755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26236607">
<a name="26236607"></a>Hammar SP. Fatal pulmonary hemorrhage after taking anticoagulation medication. <i>Respir Med Case Rep</i>. 2015;15:66-70. doi:10.1016/j.rmcr.2015.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26236607/pubmed" id="26236607" target="_blank">26236607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29886103">
<a name="29886103"></a>Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. <i>Vascul Pharmacol</i>. 2019;113:86-91. doi:10.1016/j.vph.2018.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29886103/pubmed" id="29886103" target="_blank">29886103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324838">
<a name="26324838"></a>Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi:10.1093/europace/euv309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26324838/pubmed" id="26324838" target="_blank">26324838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26022637">
<a name="26022637"></a>Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26022637/pubmed" id="26022637" target="_blank">26022637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21750584">
<a name="21750584"></a>Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney Int</i>. 2011;80(6):572-586. doi:10.1038/ki.2011.223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21750584/pubmed" id="21750584" target="_blank">21750584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33023325">
<a name="33023325"></a>Hess CN, Bonaca MP. Contemporary review of antithrombotic therapy in peripheral artery disease. <i>Circ Cardiovasc Interv</i>. 2020;13(10):e009584. doi:10.1161/CIRCINTERVENTIONS.120.009584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33023325/pubmed" id="33023325" target="_blank">33023325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26195125">
<a name="26195125"></a>Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre [published online July 21, 2015. <i>Clin Res Cardiol</i>. 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26195125/pubmed" id="26195125" target="_blank">26195125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29561531">
<a name="29561531"></a>Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). <i>Reg Anesth Pain Med</i>. 2018;43(3):263-309. doi:10.1097/AAP.0000000000000763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29561531/pubmed" id="29561531" target="_blank">29561531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.1">
<a name="Hull.1"></a>Hull RD. Venous thromboembolism: anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28009449">
<a name="28009449"></a>Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.<i> Eur J Haematol</i>. 2017;98(4):393-397. doi:10.1111/ejh.12844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28009449/pubmed" id="28009449" target="_blank">28009449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24657685">
<a name="24657685"></a>Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. <i>J Am Coll Cardiol</i>. 2014;63(20):2141-2147. doi:10.1016/j.jacc.2014.02.549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/24657685/pubmed" id="24657685" target="_blank">24657685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33079786">
<a name="33079786"></a>Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. <i>Eur J Gastroenterol Hepatol</i>. 2021;33(6):911-916. doi:10.1097/MEG.0000000000001958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33079786/pubmed" id="33079786" target="_blank">33079786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26725062">
<a name="26725062"></a>Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. <i>Dig Dis Sci</i>. 2016;61(6):1721-1727. doi:10.1007/s10620-015-4012-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26725062/pubmed" id="26725062" target="_blank">26725062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32583975">
<a name="32583975"></a>Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. <i>ESC Heart Fail.</i> 2020;7(5):2032-2041. doi:10.1002/ehf2.12718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32583975/pubmed" id="32583975" target="_blank">32583975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29079069">
<a name="29079069"></a>Ismail R, Zaghrini E, Hitti E. Spontaneous spinal epidural hematoma in a patient on rivaroxaban: case report and literature review. <i>J Emerg Med</i>. 2017;53(4):536-539. doi:10.1016/j.jemermed.2017.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29079069/pubmed" id="29079069" target="_blank">29079069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33275697">
<a name="33275697"></a>Jacobson-Kelly AE, Samuelson Bannow BT. Abnormal uterine bleeding in users of rivaroxaban and apixaban. <i>Hematology Am Soc Hematol Educ Program</i>. 2020;2020(1):538-541. doi:10.1182/hematology.2020000166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33275697/pubmed" id="33275697" target="_blank">33275697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Janssen Medical Information and Services. Xarelto medical information [written communication]. Janssen Pharmaceuticals; May 7, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. <i>Circulation</i>. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21874549">
<a name="21874549"></a>Jaeger M, Jeanneret B, Schaeren S. Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban). <i>Eur Spine J</i>. 2012;21 Suppl 4(Suppl 4):S433-S435. doi:10.1007/s00586-011-2003-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21874549/pubmed" id="21874549" target="_blank">21874549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35547458">
<a name="35547458"></a>Jarboe L, Dadlani A, Bandikatla S, Wade R, Barve A. Drug use evaluation of direct oral anticoagulants (DOACs) in patients with advanced cirrhosis. <i>Cureus</i>. 2022;14(4):e24029. doi:10.7759/cureus.24029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35547458/pubmed" id="35547458" target="_blank">35547458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730627">
<a name="32730627"></a>Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. <i>Eur Heart J Cardiovasc Pharmacother.</i> 2021;7(5):398-404. doi:10.1093/ehjcvp/pvaa096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32730627/pubmed" id="32730627" target="_blank">32730627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26111247">
<a name="26111247"></a>Jun JH, Hwang JC. Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. <i>JAMA Ophthalmol</i>. 2015;133(10):1184-1186. doi:10.1001/jamaophthalmol.2015.2069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26111247/pubmed" id="26111247" target="_blank">26111247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582928">
<a name="18582928"></a>Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. <i>Lancet</i>. 2008;372(9632):31-39. doi:10.1016/S0140-6736(08)60880-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/18582928/pubmed" id="18582928" target="_blank">18582928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34026385">
<a name="34026385"></a>Katel A, Aryal M, Neupane A, et al. Efficacy and safety of direct oral anticoagulants in venous thromboembolism compared to traditional anticoagulants in morbidly obese patients: a systematic review and meta-analysis. <i>Cureus</i>. 2021;13(4):e14572. doi:10.7759/cureus.14572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34026385/pubmed" id="34026385" target="_blank">34026385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi:10.1378/chest.11-2301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34285756">
<a name="34285756"></a>Khan FY, Sulaiman TO. Anaphylaxis following rivaroxaban ingestion: report of an extremely rare case. <i>Pan Afr Med J</i>. 2021;38:333. Published 2021 Apr 6. doi:10.11604/pamj.2021.38.333.28401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34285756/pubmed" id="34285756" target="_blank">34285756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176890">
<a name="32176890"></a>Khan SU, Osman M, Khan MU, et al. Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Ann Intern Med</i>. 2020;172(7):474‐483. doi:10.7326/M19-3763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32176890/pubmed" id="32176890" target="_blank">32176890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25055834">
<a name="25055834"></a>Königsbrügge O, Langer M, Hayde M, Ay C, Pabinger I. Oral anticoagulation with rivaroxaban during pregnancy: a case report. <i>Thromb Haemost</i>. 2014;112(6):1323-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25055834/pubmed" id="25055834" target="_blank">25055834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30396779">
<a name="30396779"></a>Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. <i>Surg Obes Relat Dis</i>. 2018;14(12):1890-1896. doi:10.1016/j.soard.2018.08.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30396779/pubmed" id="30396779" target="_blank">30396779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28121368">
<a name="28121368"></a>Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. <i>Br J Clin Pharmacol</i>. 2017;83(7):1466-1475. doi:10.1111/bcp.13243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28121368/pubmed" id="28121368" target="_blank">28121368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21039764">
<a name="21039764"></a>Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. <i>Br J Clin Pharmacol.</i> 2010;70(5):703-712. doi:10.1111/j.1365-2125.2010.03753.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21039764/pubmed" id="21039764" target="_blank">21039764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294275">
<a name="23294275"></a>Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. <i>Br J Clin Pharmacol</i>. 2013;76(1):89-98. doi:10.1111/bcp.12054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/23294275/pubmed" id="23294275" target="_blank">23294275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J<i> Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27632140">
<a name="27632140"></a>Kunk PR, Brown J, McShane M, Palkimas S, Gail Macik B. Direct oral anticoagulants in hypercoagulable states.<i> J Thromb Thrombolysis</i>. 2017;43(1):79-85. doi:10.1007/s11239-016-1420-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27632140/pubmed" id="27632140" target="_blank">27632140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31133411">
<a name="31133411"></a>Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. <i>Lancet Haematol</i>. 2019;6(7):e359-e365. doi:10.1016/S2352-3026(19)30086-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31133411/pubmed" id="31133411" target="_blank">31133411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34115699">
<a name="34115699"></a>Lamarche MC, Alrajhi E, Wells PS. Direct oral anticoagulant use in special populations. <i>Curr Opin Pulm Med</i>. 2021;27(5):311-318. doi:10.1097/MCP.0000000000000787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34115699/pubmed" id="34115699" target="_blank">34115699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30036784">
<a name="30036784"></a>Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. <i>Thromb Res</i>. 2018;169:123-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30036784/pubmed" id="30036784" target="_blank">30036784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18579812">
<a name="18579812"></a>Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.<i> N Engl J Med.</i> 2008;358(26):2776-2286. doi:10.1056/NEJMoa076016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/18579812/pubmed" id="18579812" target="_blank">18579812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33351124">
<a name="33351124"></a>Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Adv</i>. 2020;4(24):6291-6297. doi:10.1182/bloodadvances.2020003238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33351124/pubmed" id="33351124" target="_blank">33351124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30546740">
<a name="30546740"></a>Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. <i>J Cardiol Cases</i>. 2013;8(1):e49-e50. doi:10.1016/j.jccase.2013.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30546740/pubmed" id="30546740" target="_blank">30546740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30740299">
<a name="30740299"></a>Lee HL, Kim L, Kim CW, Kim JS, Nam HS, Ryu JS. Case of both rivaroxaban- and dabigatran-induced leukocytoclastic vasculitis, during management of pulmonary thromboembolism. <i>Respir Med Case Rep</i>. 2019;26:219-222. doi:10.1016/j.rmcr.2019.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30740299/pubmed" id="30740299" target="_blank">30740299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leung.1">
<a name="Leung.1"></a>Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36106537">
<a name="36106537"></a>Levine GN, McEvoy JW, Fang JC, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(15):e205-e223. doi:10.1161/CIR.0000000000001092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/36106537/pubmed" id="36106537" target="_blank">36106537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885997">
<a name="32885997"></a>Levito MN, Coons JC, Verrico MM, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. <i>Ann Pharmacother</i>. Published September 4, 2020. doi:10.1177/1060028020956271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32885997/pubmed" id="32885997" target="_blank">32885997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25155865">
<a name="25155865"></a>Liakoni E, Rätz Bravo AE, Terracciano L, Heim M, Krähenbühl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. <i>JAMA Intern Med</i>. 2014;174(10):1683-1686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25155865/pubmed" id="25155865" target="_blank">25155865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29120909">
<a name="29120909"></a>Licata A, Puccia F, Lombardo V, et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. <i>Eur J Gastroenterol Hepatol</i>. 2018;30(2):226-232. doi:10.1097/MEG.0000000000001030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29120909/pubmed" id="29120909" target="_blank">29120909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins L, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2012;141(2)(suppl):e495-e530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27061271">
<a name="27061271"></a>Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. <i>J Thromb Haemost</i>. 2016;14(6):1206-1210. doi:10.1111/jth.13330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27061271/pubmed" id="27061271" target="_blank">27061271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lip.1">
<a name="Lip.1"></a>Lip G, Hull RD. Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lip.2020">
<a name="Lip.2020"></a>Lip GYH. Acute coronary syndrome: Anticoagulation in medically treated patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30144419">
<a name="30144419"></a>Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. <i>Chest</i>. 2018;154(5):1121-1201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30144419/pubmed" id="30144419" target="_blank">30144419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26379302">
<a name="26379302"></a>Madhisetti KR, Mathew M, George M, Pillai SS. Spinal epidural haematoma following rivaroxaban administration after total knee replacement. <i>Indian J Anaesth</i>. 2015;59(8):519-521. doi:10.4103/0019-5049.163006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26379302/pubmed" id="26379302" target="_blank">26379302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699660">
<a name="31699660"></a>Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematol</i>. 2020;7(1):e18-e27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31699660/pubmed" id="31699660" target="_blank">31699660</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Male C, Lensing AWA, Palumbo JS, et al. Supplementary appendix: rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial [published online November 4, 2019]. <i>Lancet Haematol</i>. 2019.</div>
</li>
<li>
<div class="reference">
                  Manning WJ. Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27299806">
<a name="27299806"></a>Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(6):1308-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27299806/pubmed" id="27299806" target="_blank">27299806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259389">
<a name="34259389"></a>Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>J Thromb Haemost</i>. 2021;19(8):1874-1882. doi:10.1111/jth.15358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34259389/pubmed" id="34259389" target="_blank">34259389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22077192">
<a name="22077192"></a>Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <i>N Engl J Med</i>. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22077192/pubmed" id="22077192" target="_blank">22077192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34712941">
<a name="34712941"></a>Michael F, Natt N, Shurrab M. Direct oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: a systematic review and meta-analysis. <i>CJC Open</i>. 2021;3(9):1169-1181. doi:10.1016/j.cjco.2021.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34712941/pubmed" id="34712941" target="_blank">34712941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25366015">
<a name="25366015"></a>Mima Y, Sangatsuda Y, Yasaka M, Wakugawa Y, Nagata S, Okada Y. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban. <i>Intern Med</i>. 2014;53(21):2523-2527. doi:10.2169/internalmedicine.53.2890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25366015/pubmed" id="25366015" target="_blank">25366015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25475601">
<a name="25475601"></a>Moore KT, Byra W, Vaidyanathan S, et al. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. <i>Br J Clin Pharmacol</i>. 2015;79(6):907-917. doi:10.1111/bcp.12559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25475601/pubmed" id="25475601" target="_blank">25475601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28601546">
<a name="28601546"></a>Moore KT, Kröll D. Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. <i>Am J Med</i>. 2017;130(9):1024-1032. doi:10.1016/j.amjmed.2017.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28601546/pubmed" id="28601546" target="_blank">28601546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512489">
<a name="27512489"></a>Myers B, Neal R, Myers O, Ruparelia M. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): a warning. <i>Obstet Med</i>. 2016;9(1):40-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27512489/pubmed" id="27512489" target="_blank">27512489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30355723">
<a name="30355723"></a>Nagaraja V, Cranney G, Kushwaha V. Spontaneous splenic rupture due to rivaroxaban. <i>Drug Ther Bull</i>. 2018;56(11):136-139. doi:10.1136/dtb.2018.11.223237rep<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30355723/pubmed" id="30355723" target="_blank">30355723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28472251">
<a name="28472251"></a>Nagasayi S, Varman S, Ting YY, Ang W. Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: a case report. <i>Age Ageing</i>. 2017;46(5):870-871. doi:10.1093/ageing/afx073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28472251/pubmed" id="28472251" target="_blank">28472251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33151401">
<a name="33151401"></a>Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. <i>Dig Dis Sci</i>. 2021;66(10):3619-3629. doi:10.1007/s10620-020-06695-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33151401/pubmed" id="33151401" target="_blank">33151401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35689140">
<a name="35689140"></a>Novak AR, Shakowski C, Trujillo TC, Wright GC, Mueller SW, Kiser TH. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. <i>J Thromb Thrombolysis</i>. 2022;54(2):276-286. doi:10.1007/s11239-022-02668-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35689140/pubmed" id="35689140" target="_blank">35689140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34820876">
<a name="34820876"></a>O'Kane CP, Avalon JCO, Lacoste JL, et al. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m<sup>2</sup>. <i>Pharmacotherapy</i>. 2022;42(2):112-118. doi:10.1002/phar.2651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34820876/pubmed" id="34820876" target="_blank">34820876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159173">
<a name="30159173"></a>Oladiran O, Segal J, Nwosu I, Nazir S. A rare case of spontaneous cardiac tamponade induced by concomitant use of rivaroxaban and amiodarone. <i>Case Rep Cardiol</i>. 2018;2018:1650716. doi:10.1155/2018/1650716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30159173/pubmed" id="30159173" target="_blank">30159173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27088353">
<a name="27088353"></a>Ozel O, Demircay E, Kircelli A, Cansever T. Atypical presentation of an epidural hematoma in a patient receiving rivaroxaban after total hip arthroplasty. <i>Orthopedics</i>. 2016;39(3):e558-e560. doi:10.3928/01477447-20160414-01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27088353/pubmed" id="27088353" target="_blank">27088353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23391196">
<a name="23391196"></a>Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. <i>J Am Coll Cardiol</i>. 2013;61(6):651-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/23391196/pubmed" id="23391196" target="_blank">23391196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21830957">
<a name="21830957"></a>Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>N Engl J Med</i>. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21830957/pubmed" id="21830957" target="_blank">21830957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patil.2019">
<a name="Patil.2019"></a>Patil T, Ikekwere C. A case report of rivaroxaban-induced urticaria and angioedema with possible cross-reaction to dabigatran. <i>J Med Cases</i>. 2019;10(12):359-363.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30349887">
<a name="30349887"></a>Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. <i>Res Pract Thromb Haemost</i>. 2018;2(4):684-688. doi:10.1002/rth2.12146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30349887/pubmed" id="30349887" target="_blank">30349887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20299623">
<a name="20299623"></a>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i>. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/20299623/pubmed" id="20299623" target="_blank">20299623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26162958">
<a name="26162958"></a>Potpara TS, Lip GY. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. <i>Prog Cardiovasc Dis</i>. 2015;58(2):177-194. doi:10.1016/j.pcad.2015.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26162958/pubmed" id="26162958" target="_blank">26162958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29367334">
<a name="29367334"></a>Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2018;49(3):46-110. doi:10.1161/STR.0000000000000158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29367334/pubmed" id="29367334" target="_blank">29367334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231094">
<a name="29231094"></a>Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. <i>N Engl J Med</i>. 2017;378(7):615-624. doi:10.1056/NEJMoa1711948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29231094/pubmed" id="29231094" target="_blank">29231094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28167634">
<a name="28167634"></a>Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in <i>Circulation</i>. 2017;135(10):e647; <i>Circulation</i>. 2017;135(24):e1144]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28167634/pubmed" id="28167634" target="_blank">28167634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32320043">
<a name="32320043"></a>Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. <i>JAMA Cardiol</i>. 2020;5(6):685-692. doi:10.1001/jamacardio.2020.0652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32320043/pubmed" id="32320043" target="_blank">32320043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23336294">
<a name="23336294"></a>Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiol Scand</i>. 2013;57(5):565-572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/23336294/pubmed" id="23336294" target="_blank">23336294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36803697">
<a name="36803697"></a>Rosovsky RP, Kline-Rogers E, Lake L, et al. Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel. <i>Am J Med</i>. 2023;136(6):523-533. doi:10.1016/j.amjmed.2023.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/36803697/pubmed" id="36803697" target="_blank">36803697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29157916">
<a name="29157916"></a>Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thromb Res</i>. 2018;163:190-195. doi:10.1016/j.thromres.2017.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29157916/pubmed" id="29157916" target="_blank">29157916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598101">
<a name="26598101"></a>Rudd KM, Winans AR, Panneerselvam N. Possible Rivaroxaban Failure during the Postpartum Period. <i>Pharmacotherapy</i>. 2015;35(11):e164-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26598101/pubmed" id="26598101" target="_blank">26598101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24681117">
<a name="24681117"></a>Russmann S, Niedrig DF, Budmiger M, et al. Rivaroxaban postmarketing risk of liver injury. <i>J Hepatol</i>. 2014;61(2):293-300. doi:10.1016/j.jhep.2014.03.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/24681117/pubmed" id="24681117" target="_blank">24681117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32223113">
<a name="32223113"></a>Samama CM, Laporte S, Rosencher N, et al; PRONOMOS Investigators. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. <i>N Engl J Med</i>. 2020;382(20):1916‐1925. doi:10.1056/NEJMoa1913808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32223113/pubmed" id="32223113" target="_blank">32223113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19878532">
<a name="19878532"></a>Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <i>J Thromb Haemost</i>. 2010;8(1):202-204. doi:10.1111/j.1538-7836.2009.03678.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/19878532/pubmed" id="19878532" target="_blank">19878532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443941">
<a name="32443941"></a>Sebaaly J, Kelley D. Direct oral anticoagulants in obesity: an updated literature review. <i>Ann Pharmacother</i>. 2020;1060028020923584. doi:10.1177/1060028020923584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32443941/pubmed" id="32443941" target="_blank">32443941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34152697">
<a name="34152697"></a>Semmler G, Pomej K, Bauer DJM, et al. Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver Int</i>. 2021;41(9):2159-2170. doi:10.1111/liv.14992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34152697/pubmed" id="34152697" target="_blank">34152697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25613925">
<a name="25613925"></a>Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. <i>Thromb Res</i>. 2015;135(4):607-9. doi:10.1016/j.thromres.2015.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25613925/pubmed" id="25613925" target="_blank">25613925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27075620">
<a name="27075620"></a>Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. <i>Thromb Haemost</i>. 2016;116(2):397-400. doi:10.1160/TH16-02-0101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27075620/pubmed" id="27075620" target="_blank">27075620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31989095">
<a name="31989095"></a>Shaw JR, Zhang T, Le Gal G, Douketis J, Carrier M. Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. <i>Res Pract Thromb Haemost</i>. 2020;4(1):131-140. doi:10.1002/rth2.12285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31989095/pubmed" id="31989095" target="_blank">31989095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17659197">
<a name="17659197"></a>Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. <i>J Am Coll Cardiol</i>. 2007;50(4):309-315. doi:10.1016/j.jacc.2007.01.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/17659197/pubmed" id="17659197" target="_blank">17659197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30656027">
<a name="30656027"></a>Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a tertiary center experience and review of the literature. <i>Clin Case Rep.</i> 2018;7(1):135-142. doi:10.1002/ccr3.1917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30656027/pubmed" id="30656027" target="_blank">30656027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31895720">
<a name="31895720"></a>Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. <i>Am J Gastroenterol</i>. 2020;115(1):18-40. doi:10.14309/ajg.0000000000000486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31895720/pubmed" id="31895720" target="_blank">31895720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25656043">
<a name="25656043"></a>Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. <i>Odontology</i>. 2015;103(3):258-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/25656043/pubmed" id="25656043" target="_blank">25656043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511863">
<a name="32511863"></a>Speed V, Green B, Roberts LN, et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. <i>J Thromb Haemost.</i> 2020;18(9):2296-2307. doi:10.1111/jth.14948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32511863/pubmed" id="32511863" target="_blank">32511863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30145946">
<a name="30145946"></a>Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. <i>N Engl J Med</i>. 2018;379(12):1118-1127. doi:10.1056/NEJMoa1805090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30145946/pubmed" id="30145946" target="_blank">30145946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31493618">
<a name="31493618"></a>Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs. <i>Thromb Res</i>. 2019;182:159-166. doi:10.1016/j.thromres.2019.08.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31493618/pubmed" id="31493618" target="_blank">31493618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28301915">
<a name="28301915"></a>Tran PN, Tran MH. Emerging role of direct oral anticoagulants in the management of heparin-induced thrombocytopenia. <i>Clin Appl Thromb Hemost</i>. 2018;24(2):201-209. doi:10.1177/1076029617696582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28301915/pubmed" id="28301915" target="_blank">28301915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19411100">
<a name="19411100"></a>Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. <i>Lancet</i>. 2009;373(9676):1673-1680. doi:10.1016/S0140-6736(09)60734-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/19411100/pubmed" id="19411100" target="_blank">19411100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31116395">
<a name="31116395"></a>Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.<i> Eur Heart J</i>. 2019;40(31):2632-2653. doi:10.1093/eurheartj/ehz372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31116395/pubmed" id="31116395" target="_blank">31116395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36571829">
<a name="36571829"></a>Vandenberk B, Altieri MH, Liu H, Raj SR, Lee SS. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. <i>Aliment Pharmacol Ther</i>. 2023;57(3):290-303. doi:10.1111/apt.17368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/36571829/pubmed" id="36571829" target="_blank">36571829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315274">
<a name="22315274"></a>Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e637S-e668S. doi:10.1378/chest.11-2306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/22315274/pubmed" id="22315274" target="_blank">22315274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32626835">
<a name="32626835"></a>Violi F, Vestri A, Menichelli D, Di Rocco A, Pastori D, Pignatelli P. Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis. <i>Hepatol Commun</i>. 2020;4(7):1034-1040. doi:10.1002/hep4.1513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32626835/pubmed" id="32626835" target="_blank">32626835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37115488">
<a name="37115488"></a>Volkl AA, Moore KT, Haskell L, Barnathan ES. Updated renal dosage recommendations for rivaroxaban in patients experiencing or at risk of thromboembolic disease. <i>Am J Cardiovasc Drugs</i>. 2023;23(3):247-255. doi:10.1007/s40256-023-00579-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/37115488/pubmed" id="37115488" target="_blank">37115488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32423697">
<a name="32423697"></a>Wang SY, Giugliano RP. Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients. <i>Am J Cardiol</i>. 2020;127:176-183. doi:10.1016/j.amjcard.2020.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32423697/pubmed" id="32423697" target="_blank">32423697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24277644">
<a name="24277644"></a>Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. <i>Am J Cardiovasc Drugs</i>. 2014;14(2):147-154. doi:10.1007/s40256-013-0055-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/24277644/pubmed" id="24277644" target="_blank">24277644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646118">
<a name="28646118"></a>Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. <i>Blood</i>. 2017;130(9):1104-1113. doi:10.1182/blood-2017-04-778993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28646118/pubmed" id="28646118" target="_blank">28646118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21332248">
<a name="21332248"></a>Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. <i>Drug Saf</i>. 2011;34(3):243-252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/21332248 /pubmed" id="21332248 " target="_blank">21332248 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27747798">
<a name="27747798"></a>Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? a review of the literature. <i>Drugs Real World Outcomes</i>. 2016;3(1):1-6. doi:10.1007/s40801-015-0056-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27747798/pubmed" id="27747798" target="_blank">27747798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28316279">
<a name="28316279"></a>Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. <i>N Engl J Med</i>. 2017;376(13):1211-1222. doi:10.1056/NEJMoa1700518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/28316279/pubmed" id="28316279" target="_blank">28316279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27396794">
<a name="27396794"></a>Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G. The direct factor Xa inhibitor rivaroxaban passes into human breast milk. <i>Chest</i>. 2016;150(1):e1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/27396794/pubmed" id="27396794" target="_blank">27396794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33191781">
<a name="33191781"></a>Willeford A, Zhu W, Stevens C, Thomas IC. Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus.<i> Ann Pharmacother</i>. 2021;55(7):839-845. doi:10.1177/1060028020975111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33191781/pubmed" id="33191781" target="_blank">33191781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292671">
<a name="34292671"></a>Willmann S, Coboeken K, Zhang Y, et al. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. <i>CPT Pharmacometrics Syst Pharmacol</i>. 2021;10(10):1195-1207. doi:10.1002/psp4.12688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/34292671/pubmed" id="34292671" target="_blank">34292671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29660785">
<a name="29660785"></a>Willmann S, Zhang L, Frede M, et al. Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations. <i>CPT Pharmacometrics Syst Pharmacol</i>. 2018;7(5):309-320. doi:10.1002/psp4.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29660785/pubmed" id="29660785" target="_blank">29660785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26718576">
<a name="26718576"></a>Wilson D, Charidimou A, Shakeshaft C, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. <i>Neurology</i>. 2016;86(4):360-366. doi:10.1212/WNL.0000000000002310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26718576/pubmed" id="26718576" target="_blank">26718576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482765">
<a name="30482765"></a>Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Adv</i>. 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/30482765/pubmed" id="30482765" target="_blank">30482765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32279215">
<a name="32279215"></a>Wojakowski E, Cheruvil C, Hassan A, et al. Albumin and bleed risk in rivaroxaban treated patients.<i> J Thromb Thrombolysis</i>. 2020;50(4):1004-1011. doi:10.1007/s11239-020-02092-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32279215/pubmed" id="32279215" target="_blank">32279215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33773756">
<a name="33773756"></a>Wu Z, Ma Y. Hypersensitivity reaction from rivaroxaban. <i>Am J Med Sci</i>. 2021;361(5):679-680. doi:10.1016/j.amjms.2020.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/33773756/pubmed" id="33773756" target="_blank">33773756</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xarelto.4">
<a name="Xarelto.4"></a>Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746227">
<a name="29746227"></a>Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <i>J Clin Oncol</i>. 2018;36(20):2017-2023. doi:10.1200/JCO.2018.78.8034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/29746227/pubmed" id="29746227" target="_blank">29746227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32246743">
<a name="32246743"></a>Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>J Thromb Haemost</i>. 2020;18(7):1672-1685. doi:10.1111/jth.14813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/32246743/pubmed" id="32246743" target="_blank">32246743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26543654">
<a name="26543654"></a>Zaarour M, Hassan S, Thumallapally N, Dai Q. Rivaroxaban-induced nontraumatic spinal subdural hematoma: an uncommon yet life-threatening complication. <i>Case Rep Hematol</i>. 2015;2015:275380. doi:10.1155/2015/275380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/26543654/pubmed" id="26543654" target="_blank">26543654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36760080">
<a name="36760080"></a>Zhao Y, Guo M, Li D, et al. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review. <i>Clin Appl Thromb Hemost</i>. 2023;29:10760296231153638. doi:10.1177/10760296231153638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/36760080/pubmed" id="36760080" target="_blank">36760080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31342343">
<a name="31342343"></a>Zhou Y, Ma J, Zhu W. Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis. <i>Am J Cardiovasc Drugs</i>. 2020;20(1):51-60. doi:10.1007/s40256-019-00362-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/31342343/pubmed" id="31342343" target="_blank">31342343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35763193">
<a name="35763193"></a>Zhuo X, Wang J, Shao L. Comparing the clinical outcomes observed with rivaroxaban versus warfarin for the management of obese patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022. doi:10.1007/s10557-022-07361-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivaroxaban-pediatric-drug-information/abstract-text/35763193/pubmed" id="35763193" target="_blank">35763193</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127822 Version 148.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
